Skip to content
naulon
Get started

No retraction, correction or concern found when last checked on Oct 15, 2026.

The anti-inflammatory and immunosuppressive effects of glucocorticoids, recent developments and mechanistic insights

Agnes E. Coutinho, Karen E. Chapman

Molecular and Cellular Endocrinology · 2011 · Review · CC BY

doi:10.1016/j.mce.2010.04.005

Abstract

Since the discovery of glucocorticoids in the 1940s and the recognition of their anti-inflammatory effects, they have been amongst the most widely used and effective treatments to control inflammatory and autoimmune diseases. However, their clinical efficacy is compromised by the metabolic effects of long-term treatment, which include osteoporosis, hypertension, dyslipidaemia and insulin resistance/type 2 diabetes mellitus. In recent years, a great deal of effort has been invested in identifying compounds that separate the beneficial anti-inflammatory effects from the adverse metabolic effects of glucocorticoids, with limited effect. It is clear that for these efforts to be effective, a greater understanding is required of the mechanisms by which glucocorticoids exert their anti-inflammatory and immunosuppressive actions. Recent research is shedding new light on some of these mechanisms and has produced some surprising new findings. Some of these recent developments are reviewed here.

Full text

From PubMed Central, U.S. National Library of Medicine, as current on Oct 17, 2026. Paragraph numbers are ours, so an answer can point at one.

Introduction

Natural and synthetic glucocorticoids remain at the forefront of anti-inflammatory and immunosuppressive therapies. They are widely used to treat both acute and chronic inflammations, including rheumatoid arthritis, inflammatory bowel disease, multiple sclerosis, psoriasis and eczema, as well as being used in treatment of certain leukaemias and in immunosuppressive regimes following organ transplant. At any one time, an estimated ∼1% of the total adult population of the UK receives oral glucocorticoid therapy. However, long-term use of oral glucocorticoids is associated with serious side effects, including osteoporosis, metabolic disease and increased risk of cardiovascular disease—in themselves, somewhat paradoxically, inflammatory conditions. Over the 60 years since the discovery of glucocorticoids, much has been learnt of the molecular mechanisms by which they act (recently reviewed;,,,,,,, and ), with milestones being the characterisation of the glucocorticoid receptor (GR) as a DNA binding protein that regulates transcription initiation (reviewed, ), the cloning of GR and the discovery that many of the immunosuppressive actions of glucocorticoids are mediated by interference with signalling by the key inflammatory transcriptional regulators; NF-κB and AP-1 (reviewed, ). However, much also remains unknown and the past few years have provided crucial mechanistic insights into the dynamic nature of GR interactions with DNA and higher order chromatin structures, into the subtleties of ligand effects on GR function, the regulation of endogenous ligand access to GR, glucocorticoid effects on leukocyte differentiation and function and the mechanistic basis for some of the repressive actions of glucocorticoids, critical for their anti-inflammatory effects.

Inflammation and its resolution

The host inflammatory response is a primary defence mechanism engaged immediately following injury or infection which is necessary to restore homeostasis following successful elimination of the injurious agent, ultimately leading to resolution and tissue repair. Although categorically distinct, the innate (the relatively non-specific immediate host defence system that provides a rapid reaction to infection and tissue damage) and adaptive (the more slowly acquired, highly antigen-specific response) immune systems interact and often overlap during an inflammatory response. Indeed, although acute inflammation is largely mediated by the innate immune system, the adaptive immune system often plays a major role in chronic inflammatory disease, with dysregulated lymphocyte responses.

Inflammation is initiated at the site of injury by resident cells, particularly mast cells and resident macrophages, which release pro-inflammatory mediators including bioactive amines, lipid mediators and cytokines—typically TNF-α and IL-1. These cause vasodilation, increased capillary permeability (humoral response) and leukocyte emigration into injured tissues (cellular response), resulting in the hallmark pain, heat, redness and swelling of inflammation as well as generating a chemotactic gradient to guide and activate recruited cells to the site of injury. Although specific characteristics depend on the immune exposure (e.g. irritant vs pathogen), the recruitment process and activation of inflammatory cells are common. Activated granulocytes, crucial to contain microbial infection, are rapidly attracted to the inflamed site, followed by monocyte emigration from blood vessels and subsequent maturation into macrophages. Once at the inflamed site, neutrophils undergo constitutive apoptosis, functionally isolating them from the inflammatory environment by loss of stimulated chemotaxis, phagocytosis, degranulation and respiratory burst, whilst at the same time, facilitating safe removal of their potentially histotoxic contents by macrophages. Foreign antigens are taken up by antigen presenting cells; particularly dendritic cells, but also macrophages, that then migrate to draining lymph nodes where they instruct the adaptive immune system (T and B lymphocytes), shaping the subsequent immune response. As the inflammatory response progresses and evolves, mononuclear cells predominate and resolution normally ensues. Successful resolution of acute inflammation is an active and highly regulated process and dependent on mechanisms engaged early in the inflammatory response that programme the trajectory and form of the subsequent resolution (reviewed, and ). Persistence of the initiating stimulus invariably leads to chronic inflammation, with the typical dysregulation between destructive inflammatory and excessive healing responses seen in diseases such as arthritis, atherosclerosis and asthma.

Glucocorticoids and inflammation

Glucocorticoids inhibit many of the initial events in an inflammatory response. They also promote the resolution of inflammation although the mechanisms by which they do so have received less attention than those associated with suppression of the initial response. Acutely, glucocorticoids inhibit the vasodilation and increased vascular permeability that occurs following inflammatory insult and they decrease leukocyte emigration into inflamed sites, effects that require new protein synthesis (reviewed ). They also alter leukocyte distribution/trafficking, death/survival and, importantly, alter cellular differentiation programmes, thus shaping the subsequent response (see below).

Most of the anti-inflammatory and immunosuppressive actions of glucocorticoids are attributable either directly or indirectly to the transcriptional effects of GR agonism which alters transcription of numerous genes in leukocytes, both up and down. Although expression of mineralocorticoid receptor (MR), which binds glucocorticoids with high affinity in the absence of 11β-hydroxysteroid dehydrogenase type 2 (11β-HSD2; see below), has been reported in immune cells (which do not normally express 11β-HSD2, ), it appears of little consequence to the anti-inflammatory effects of glucocorticoids, and may even have pro-inflammatory effects. It should also be noted that some anti-inflammatory effects of glucocorticoids are apparent within minutes and a number are independent of the transcriptional effects of GR (see for example, and ). Notably, glucocorticoids repress transcription of many genes encoding pro-inflammatory cytokines and chemokines, cell adhesion molecules and key enzymes involved in the initiation and/or maintenance of the host inflammatory response (reviewed, and ). Many of these genes are commonly over-expressed during chronic non-resolving inflammation. Intriguingly, recent data have shown that whereas glucocorticoid administration 1 h following endotoxin (lipopolysaccharide, LPS) challenge is immunosuppressive, administration of the same glucocorticoid dose prior to LPS challenge augments immune responses. This was true in both the brain and the liver, raising the possibility that chronic hypothalamic–pituitary–adrenal (HPA) axis activation (as may occur during chronic inflammation for example) exaccerbates inflammation in the brain and elsewhere (reviewed in ).

Until recently, it was widely believed that the repressive, anti-inflammatory effects of glucocorticoids were dependent on the ability of GR to inhibit the activity of crucial transcriptional regulators of pro-inflammatory genes, including NF-κB and AP-1, by a mechanism termed “transrepression”. This contrasted with the metabolic actions of glucocorticoids which require gene activation by GR. This view has recently been revised, with the discovery that key anti-inflammatory actions of glucocorticoids are brought about through gene activation (and see below).

The repressive actions of glucocorticoids

The ability of GR to repress the activity of NF-κB and AP-1 as well as other key immunomodulatory transcription factors has been a major focus of research into the mechanisms underlying the anti-inflammatory effects of glucocorticoids. Although a role for transactivation by GR in repression of NF-κB was implicated – inducing expression of the NF-κB inhibitor, IκBα – this was restricted to certain cell types and did not appear to be a universal mechanism. Biochemical and genetic evidence suggested that negative regulation by a transrepression (or “tethering”) mechanism independent of DNA binding by GR underpinned the repressive effects of glucocorticoids (reviewed and ) and this, by extension, was thought to be responsible for their clinical efficacy. In contrast to gene activation by GR, which at the time was believed to occur exclusively through homodimers of GR binding to palindromic glucocorticoid response elements (GREs), transrepression involves direct protein-protein binding of GR to other transcription factors and interference with their mechanism of action. The interaction requires the DNA binding domain of GR (but not DNA binding per se) and does not require conventional homodimerisation of GR. Transrepression was not affected by mutation of alanine 458 to threonine (A458T) within the dimerisation interface of the DNA binding domain that dramatically reduces GR transactivation of the MMTV-LTR promoter and the tyrosine aminotransferase (TAT) gene promoter, both classically activated by GR through well-characterised palindromic GREs. Considerable support for the transrepression hypothesis came from in vivo experiments in mice in which the wild-type GR was replaced by the dimerisation (dim) mutant (GRdim mice). Glucocorticoid-mediated repression of AP-1-dependent transcription and other pro-inflammatory genes was intact in these mice, in contrast to defective GRE-dependent transactivation. However, transactivation of some genes, including that encoding phenylethanolamine N-methyltrasferase (PNMT), remained intact. It has since emerged that the GRE in the PNMT gene belongs to a different class of GRE to the palindromic consensus, and comprises a series of repeated half sites to which GR directly binds to activate transcription from the PNMT promoter. Dual specificity phosphatase (DUSP) 1, also known as MKP-1 (mitogen activated protein kinase [MAPK] phosphatase 1), a crucial anti-inflammatory gene, also remains fully inducible in GRdim mice, offering an alternative interpretation of their phenotype. Glucocorticoid induction of DUSP1 may have some similarity to that of PNMT, as recent work has shown the glucocorticoid responsive region in the DUSP1 gene contains 3 closely spaced half sites, although a tethering mechanism of activation dependent on C/EBPβ has also been implicated. Thus, at least some, but not all, of the dimerisation-independent repressive actions of glucocorticoids may be wholly or partly dependent on induction of DUSP1. Consistent with this, glucocorticoids failed to suppress zymosan-induced inflammation in DUSP1−/− mice, whereas inflammation was suppressed in control mice. However, DUSP1−/− mice remain sensitive to the suppressive effects of glucocorticoids in mast cell-dependent anaphylaxis, implicating other mechanisms in the anti-inflammatory action of glucocorticoids in this model of inflammation. Intriguingly, DUSP1−/− mice are resistant to diet-induced obesity, raising the possibility that DUSP1 may also be involved in some of the metabolic effects of glucocorticoids.

The anti-inflammatory actions of glucocorticoid-induced genes have been recently reviewed. Briefly, as well as DUSP1 and IκB, this class of genes includes IL-10, a potent immunomodulatory and anti-inflammatory cytokine, Glucocorticoid-induced leucine zipper (GILZ), a protein whose mechanism of action is unclear but which interacts with, and inhibits the function of, NFκB and AP-1 and annexin AI (AnxA1), a calcium-dependent phospholipid binding protein. GILZ knockout mice have not been reported, but AnxA1-deficient mice show defective glucocorticoid suppression of inflammation in carrageenin-induced oedema, zymosan-induced peritonitis and antigen-induced arthritis. IL-10-deficient mice develop autoimmune disease and chronic inflammation, but effects of glucocorticoids in these mice have not been reported. However, IL-10 has been implicated in negative regulation of corticosterone synthesis, acting at the adrenal gland, providing a plausible homeostatic mechanism to terminate HPA axis activation once inflammation is resolving. Like IL-10, administration of AnxA1 can mimic a subset of the effects of glucocorticoids (although in T cells, AnxA1 effects may be opposite to those of glucocorticoids). Similarly, ectopic expression of GILZ in T cells and dendritic cells can mimic some of the effects of glucocorticoid. Indeed, some of the effects of both IL-10 and AnxA1 may even be mediated by GILZ, although as IL-10, AnxaA1 and GILZ all alter differentiation or activation state of immune cells, such conclusions remain tentative.

Glucocorticoids induce GILZ in a variety of cell types, both immune and non-immune, through palindromic GREs in the 5′-flanking region of the GILZ gene, dependent on dimerisation of GR. How they regulate IL-10 and AnxA1 remains unclear. In vitro, glucocorticoids increase IL-10 expression in monocytes, macrophages and, dependent on antigen presenting cells, in T cells, but whether this is related to glucocorticoid-driven alterations in cellular differentiation (see below) or whether glucocorticoid-induced IL-10 indeed mediates some of the effects of glucocorticoids on differentiation as suggested remains unknown. Glucocorticoids increase AnxA1 expression on human monocytes and neutrophils in vivo and in pituitary folliculostellate cells in vitro and whilst the underlying mechanisms remain unclear, they appear to involve both non-genomic and genomic actions of glucocorticoids, the latter both modest and relatively slow. Moreover, glucocorticoids decrease AnxA1 mRNA in T cells, raising the possibility that glucocorticoid regulation in adaptive and innate immune cells may be related to differentiation/activation state rather than being a direct regulation.

Context-specific gene regulation by GR

Transcriptional repression by GR has always been the subject of debate, as alluded to above, including the extent to which it is dependent or independent of direct GR DNA binding. However, it is agreed that gene activation requires DNA binding by GR. Much of the early work on GR transcriptional activation was based around a consensus GR binding site, comprising two 6 bp “half sites” arranged in an inverted repeat (palindrome) separated by a 3 bp spacer, derived from comparisons of around 20 GR binding sites in promoters including the MMTV-LTR. Subsequent work has confirmed this but additionally shown GR-mediated gene regulation to be much more complex (reviewed in detail in,,, and ). A recent unbiased screen of GR binding sites coupled with transcriptome analysis showed that genes activated by glucocorticoid had GR bound within a median distance of 11 kb from the transcription start site whereas repressed genes had GR bound a median of 146 kb from the transcription start site, suggesting that repression occurs independently of promoter-proximal GR binding. In silico prediction, genome scanning, chemically directed sequence-specific disruption of GR binding and chromatin immunoprecipitation experiments have shown that sequences that match the GR consensus do not necessarily bind GR in cells and that disruption of GR binding to the conserved half site sequence 5′-WGWWCW-3′ (where W = A/T) only affects a minority of glucocorticoid-regulated genes, both repressed and activated. It has long been clear that many GR binding sites (core sites) are embedded in “composite” glucocorticoid responsive units (e.g., and ). Core GR binding sites vary considerably around the consensus although the precise sequence in and immediately around the core GR binding site in a gene (the glucocorticoid responsive unit) is highly conserved between species. Moreover, actual occupancy by GR is influenced by post-translational modification and depends on cell-specific factors. Thus, efficient glucocorticoid regulation depends on concomitant binding by other transcription factors at composite elements, to the extent that GR may “tether” at some promoters, retained principally by protein–protein interactions rather than direct interactions with DNA. Given that GR homodimerisation, at least of the isolated DNA binding domain, only occurs on DNA binding, then monomers of GR may bind to divergent sequences at composite response elements or by tethering to other transcription factors. Thus, the context of the GR binding site is crucial with the outcome – repression, activation or even specificity (MR vs GR) – dependent on the cell-specific complement of transcription factors. Whether and how GR contacts DNA might be critical. The GR DNA binding sequence itself acts as an allosteric regulator of GR function, dictating the pattern of regulation that ensues following GR binding. DNA binding induces conformational changes in the dimerisation interface that expose otherwise silent transcriptional activation surfaces. These conformational changes are exquisitely sensitive to the DNA sequence, with single base pair differences differentially affecting GR conformation and transcriptional regulation. Further complexity is revealed at the level of chromatin, where GR binding is highly dynamic and invariably occurs at either consititutive or hormone inducible nuclease accessible sites (regions of “open” chromatin) at which the requirement for chromatin remodelling complexes differs. These dynamic and gene-specific differences in chromatin remodelling by GR are likely to be highly cell-specific and could underlie the complex kinetics of glucocorticoid responses, where glucocorticoid responsive genes may exhibit alternate activation and repression, with poor correlation in some cases between GR binding to response elements and target gene response. Elucidating the nature of GR interactions with target genes, especially in the immune system, will be crucial to understanding their anti-inflammatory effects, but the challenge will be to establish these actions in physiologically relevant settings.

Glucocorticoid effects on immune cell function

GR is widely, almost ubiquitously, expressed. Thus, glucocorticoids affect virtually all immune cells and, moreover, precise effects depend upon differentiation and activation state of the cell, making interpretation of in vivo effects in specific cell populations difficult. Nevertheless, several lines of mice with global alteration of GR have provided vital new information about the functions of GR both in regulating the HPA axis and immunity and inflammation. Mice with hypomorphic (GRhypo) or null alleles of GR die neonatally, but haematopoietic progenitors from these mice have been used to reconstitute the immune system in lethally irradiated wild-type mice. Other models survive and include mice with increased GR density (yGR mice with 2 extra GR alleles), with decreased GR density (GR+/− mice and anti-sense rat GR transgenic mice, ) and mice with altered GR function; GRdim and GRM601L mice (a knock-in of a human GR mutant with increased glucocorticoid sensitivity). In all these models the HPA axis is affected because of the central feedback actions of glucocorticoids, compensating for altered GR function in all but the hypomorphic and null mice. All show inflammatory/immune phenotypes (see below). Recent experiments using conditional GR knockout mice as well as transgenic mice have also shed light on the cell-specific functions of GR during immune and inflammatory responses. Tissue-specific models reported include T cell-specific or myeloid cell knockout of GR as well as transgenic mice with thymus over- and under-expression of GR. Some of the immune and inflammatory phenotypes of these various mice have been reviewed in detail elsewhere and are discussed below.

GR functions in T cells

Glucocorticoid action in T cells and, in particular, in thymus, where naive T cells (that have yet to encounter antigen) develop, has been the subject of intensive research yet remains highly controversial. During T cell development, immature thymocytes progress from double negative (for the CD4 and CD8 T cell markers) to double positive cells (CD4+CD8+) which undergo positive selection (only thymocytes that bind MHC complexed with self-antigen survive) and negative selection (against cells that interact too strongly with self-antigen) to mature into either CD4+ or CD8+ single positive cells; the T cell repertoire. Double positive cells, the majority of the thymocyte population, are highly sensitive to glucocorticoid-induced apoptosis, effective at physiological levels of glucocorticoids. Much in vitro evidence points to a crucial role for glucocorticoids in regulating T cell number, repertoire and function, yet the in vivo evidence is discordant. This topic has been extensively reviewed and will only be briefly discussed here. Suffice it to say, complete lack of GR globally, in T cells alone or inability to dimerise (GRdim mice) does not appear to affect thymocyte number or subsets, although these thymocytes are completely glucocorticoid resistant (reviewed in ). Conversely, mice with a global increase in GR levels (yGR mice) or function (GRM604L mice) have normal thymocyte numbers and subsets, yet both lines of mice show increased glucocorticoid sensitivity of thymocytes in vitro. However, transgenic mice with increased GR in T cells (directed by the proximal Lck promoter or a doxycycline-inducible CD2 promoter) show reduced thymic cellularity with increased thymocyte sensitivity to glucocorticoids in vitro. Finally, in 2 of 3 models in which GR density is reduced by expression of antisense GR either globally (neurofilament promoter) or in T cells (Lck promoter), thymic cellularity is increased, albeit modestly. However, the 3rd antisense model (also using the proximal Lck promoter) showed the opposite effect, with reduced cellularity and altered T cell repertoire. Reconciling these discrepant results will no doubt inform on the cell-specific roles of GR in thymus and T cell selection.

T cell GR is required to survive lethal activation of T cells. Mice with conditional deletion of GR in T cells (in which the Lck promoter was used to drive Cre recombinase-mediated excision of a “floxed” GR gene) showed increased mortality following activation of T cells either by antibody to CD3ɛ or following injection of bacterial superantigen (staphylococcal enterotoxin A), due to failure to repress cyclooxygenase (COX)-2 expression. Interestingly, these mice showed much worse tissue damage in the gastrointestinal tract than control mice following T cell activation, although damage in other tissues was similar, suggesting a particular role for GR in T cells within the gastrointestinal mucosa in controlling immune activation.

GR is also required in peripheral T cells for the immunosuppressive effects of glucocorticoid therapy in experimental autoimmune encephalomyelitis (EAE; a mouse model of multiple sclerosis). Like chimeric mice with GR−/− haemotopoietic cells (following lethal irradiation of wild-type mice and reconstitution with GR−/− haemotopoietic cell progenitors), GRLckCre mice (a second line, distinct from the mice mentioned above) showed an earlier onset of disease than controls (indicating a critical role for endogenous glucocorticoid) which was refractory to dexamethasone treatment. In control mice, but not in GRLckCre mice, glucocorticoid therapy induced apoptosis of T cells in peripheral lymphoid organs and down-regulated adhesion molecules, thus reducing migration of T cells to the site of inflammation. Importantly, mice heterozygous for a null mutation of GR (GR+/− mice), with half the normal level of GR, showed a more severe EAE disease course with greater inflammation in the spinal cord than control mice and were resistant to the suppressive effects of a sub-maximal dose of dexamethasone (4 mg/kg) that was effective in normal mice. This suggests that GR density in peripheral T cells is a critical determinant of sensitivity and that despite the presence of functional GR, clinical glucocorticoid resistance can arise. However, in sepsis, another model of inflammation, GR in T cells is not required for glucocorticoid suppression (cited as unpublished data in ).

GR functions in myeloid cells

The phenotype of mice with a conditional deletion of GR in myeloid cells has been reported by 2 groups. In both cases, the LysM promoter was used to drive Cre recombinase-mediated excision of a floxed GR gene. This results in efficient excision in macrophages and granulocytes in GRLsyMCre mice, with variable excision in other myeloid cell types including dendritic cells and mast cells. Similar to adrenalectomised mice, GRLsyMCre mice showed greater mortality following LPS challenge than control mice. This was attributed to failure to induce DUSP1, required to inhibit p38 MAPK activated by engagement of toll-like receptor (TLR) 4 by LPS. However, given that GRdim mice show normal glucocorticoid induction of DUSP1 in macrophages, yet are susceptible to lethal sepsis (cited in ) as unpublished data), it is likely that other important myeloid cell anti-inflammatory actions of glucocorticoids are also required in this model of inflammation. In contrast to endotoxaemia, mice with deletion of GR in myeloid cells remained fully sensitive to therapeutic suppression of EAE by glucocorticoid, although they did show exacerbated disease.

GR in myeloid cells, but not T cells, are required for glucocorticoid suppression of contact allergy (a T cell-dependent delayed-type hypersensitivity response, such as occurs in response to metals or poison ivy). Whereas T cell deletion of GR (GRLckCre) had no effect, deletion of GR in myeloid cells (GRLysMCre) abolished glucocorticoid suppression of inflammation, allowed persistent leukocyte infiltration into the inflamed area and impaired glucocorticoid suppression of macrophage IL-1β, MCP-1 and MIP-2 secretion. Interestingly, in contrast to irritant-induced skin inflammation, glucocorticoid repression of T cell-dependent contact allergy did not occur in GRdim mice, and although TNFα remained glucocorticoid-suppressible in GRdim macrophages, MCP-1 and MIP-2 were not repressed. Thus, the immunosuppressive effects of GR are likely to result from multiple mechanisms, which are cell-type and stimulus-type dependent.

The elucidation of the cell-specific roles of GR within other leukocyte populations and also within T cell subsets will be informed by future conditional knockouts. Knockout of GR in mast cells, a major target in glucocorticoid suppression of allergic responses, will be revealing, as will GR disruption in B cells. Like T cells, glucocorticoids also reduce circulating B cell numbers. Consistent with this, blood lymphocyte levels (T and B cells) as well as monocyte/neutrophils (CD11b+ cells) were markedly reduced following reconstitution of irradiated wild-type mice with GRM604L glucocorticoid-hypersensitive haematopoietic progenitor cells. Elucidation of the underlying mechanisms may be helpful in the treatment of some early T and B cell leukaemias that respond to glucocorticoids.

Glucocorticoids alter leukocyte differentiation programmes

As well as profoundly affecting the function of immune cells, glucocorticoids also alter differentiation programmes of progenitor cells. Thus, chronically stressful conditions (when endogenous glucocorticoid production is high) or glucocorticoid pharmacotherapy may alter immune cell differentiation and indeed, probably shape the immune response as it develops. This may be of relevance in the induction of peripheral tolerance to allergenic stimuli, a major clinical application of glucocorticoids.

Dendritic cells are key antigen presenting cells that bridge the innate and adaptive immune systems. Immature dendritic cells are activated when they capture, process, then present antigens, maturing into immunostimulatory cells in the process. Activated dendritic cells migrate to draining lymph nodes where they interact with naive T cells to instruct the adaptive immune response. Suppression of dendritic cells maturation and function has been implicated in the immunosuppressive effects of glucocorticoids. However, glucocorticoids do not merely suppress dendritic cell activity, but reprogramme them to so-called “tolerogenic dendritic cells” which can elicit a state of hypo-responsiveness in T cells and induce formation of regulatory T (Treg) cells. Differentiation of tolerogenic dendritic cells is dependent, at least in part, on GILZ. Exactly how GILZ mediates anti-inflammatory effects currently remains unclear, although it is likely to depend on protein-protein interactions between GILZ and a variety of intracellular signalling proteins, including the inflammatory regulators NF-κB and activated Ras, the latter being a key protein in signalling to MAP kinases. Nevertheless, the active suppression of antigen-specific immunity through Treg induction by glucocorticoid-programmed dendritic cells undoubtedly contributes to their efficacy in allergic disease and probably other chronic inflammatory diseases. Interestingly, as well as promoting a tolerogenic phenotype in dendritic cells, glucocorticoids may also contribute to tolerance through direct effects on T cells. Stimulation of CD4+ cells in the presence of glucocorticoid (or even more effectively, together with vitamin D3) induced IL-10-secreting Treg cells, able to regulate Th1 responses and autoimmunity. A more complete understanding of these effects will improve clinical use of glucocorticoids.

These dramatic effects of glucocorticoids on haematopoietic cell differentiation are not restricted to dendritic cells. Glucocorticoids induce a similar anti-inflammatory phenotype in macrophage differentiation. Work over the past decade has shown that a key mechanism to resolve inflammation is the recognition and phagocytosis of dying cells by monocytes/macrophages. Glucocorticoids increase macrophage phagocytosis of apoptotic cells, a strongly anti-inflammatory process, by at least 2 mechanisms. In already differentiated human monocyte-derived macrophages, they induce a protein S/Mer tyrosine kinase-dependent apoptotic cell clearance pathway. However, when included during the differentiation process, glucocorticoids also programme blood monocyte differentiation into a highly phagocytic “anti-inflammatory” macrophage phenotype, a phenomenon that can be modulated by local cytokine environment, may be mediated in part by Anxa1 and which also includes induction of Mer tyrosine kinase as well as other anti-inflammatory genes important in phagocytosis, chemotaxis and protection against oxidative stress. Whether GILZ plays a similar important role in the glucocorticoid-directed macrophage differentiation programme to that it plays in re-programming dendritic cells has not been addressed. Interestingly, these glucocorticoid-programmed macrophages show down-regulation of adhesion-related proteins suggesting they have increased migratory properties. Importantly, in mouse monocytes, glucocorticoids induced a phenotype with low adhesiveness, high migratory capacity and markers suggestive of a tumour-associated macrophage phenotype, believed to be important for tumour-associated immunosuppression. The authors further speculate that this may be a mechanism underlying the higher incidence and faster progression of tumours in patients on long-term glucocorticoid therapy. Intriguingly, in aged mice, elevated plasma glucocorticoid levels were associated with an increase in the proportion of suppressor macrophages in spleen, suggesting that endogenous glucocorticoids may regulate macrophage phenotype in vivo, similar to the potent synthetic glucocorticoids used in the in vitro studies. However, further clarification of the macrophage phenotypes involved in both the in vivo and in vitro studies is required before conclusions can be drawn concerning the involvement of glucocorticoids in suppressor macrophage differentiation and function.

GR agonists; pharmacological and physiological GR activation

A variety of GR ligands are in use clinically which have different potency and differ in their biological efficacy. Different ligands clearly induce different conformations of GR that have different gene regulatory properties - indeed this has recently been exploited in the search for “dissociated” ligands which dissociate the beneficial anti-inflammatory (repressive) effects of GR agonism from the unwanted metabolic (activation) effects. Structural studies, including of dexamethasone, fluticasone fuorate and, more recently non-steroidal agonists bound in the GR ligand binding domain have shown that GR readily changes conformation to accommodate large moieties on the ligand and have illustrated new possibilities for mode of ligand binding to GR. Thus, different conformations of GR resulting from different ligand associations may have cell-specific and target gene-specific properties that offer potential for future pharmacological exploitation.

Endogenous glucocorticoid action

Much of the research on the anti-inflammatory and immunosuppressive actions of glucocorticoids has been carried out with saturating levels of synthetic hormones. In humans, these include prednisolone and methylprednisolone, but in animal models and in vitro, dexamethasone is most commonly used. This has provided an over-simplified view of the immunomodulatory actions of glucocorticoids and may have overlooked important opportunities for therapeutic manipulation of endogenous glucocorticoid action. This subject has been previously reviewed, and the discussion here is restricted to more recent insights.

Synthetic glucocorticoids, especially dexamethasone, have higher affinity, greater bioavailability (unlike the natural hormones, most bind poorly or not at all to corticosteroid binding globulin) and are poorly metabolised, thus they persist in plasma much longer than endogenous glucocorticoids (cortisol, corticosterone). Moreover, the endogenous hormones are released from the adrenal gland in both a circadian and a highly pulsatile (ultradian) manner (reviewed in). Recent work from the laboratories of Gordon Hager and Stafford Lightman has shown that this pulsatile release of glucocorticoids is coupled to a highly dynamic pattern of GR-mediated transcriptional bursts, driven by rapid recycling of GR occupancy of chromatin binding sites in response to the hormonal pulses in vivo as well as in vitro. This pulsatility did not occur with constant administration of hormone, nor did it happen with synthetic ligands, including dexamethasone, which failed to cause significant ultradian cycling of GR on chromatin and consequently failed to couple fluctuations in hormone levels with transcriptional response. Thus, transcriptional output can be profoundly altered by synthetic GR ligands or even with natural hormones if not administered in the natural pattern. Moreover, basal levels of glucocorticoids in vivo exert tonic effects. Thus, macrophages elicited by thioglycollate in the peritoneum of adrenalectomised rats behaved very differently to macrophages from sham operated rats, with much greater TNFα secretion and NO production in the unstimulated state, which could only be marginally increased by LPS/IFNγ stimulation. Cytokines themselves are potent activators of the HPA axis, and may permanently programme endogenous glucocorticoid secretion when elevated in early life. Importantly, when the HPA axis is activated, not only is plasma cortisol elevated (corticosterone in rodents), but so is plasma cortisone (11-dehydrocorticosterone in rodents), itself intrinsically inert due to poor binding to GR, but which is available in plasma (it shows negligible binding to corticosteroid binding globulin) and which can be readily enzymatically converted inside cells to the active steroid by 11β-hydroxysteroid dehydrogenase type 1 (11β-HSD1).

11β-HSD1 amplifies glucocorticoid action within cells

The last 2 decades have produced a wealth of information on the importance of pre-receptor steroid metabolism. By interconverting active glucocorticoids and inert 11-keto metabolites (cortisone, 11-dehydrocorticosterone), 11β-HSD modulates intracellular access of glucocorticoid to receptors. Type 2 11β-HSD (11β-HSD2) inactivates glucocorticoids in vivo, thus protecting the otherwise non-selective MR from occupation by glucocorticoids. In contrast, because 11β-HSD1 reactivates glucocorticoids, it increases intracellular glucocorticoid concentration. In addition to cortisone (the natural metabolite), certain synthetic steroids (notably prednisone/prednisolone) are also substrates for the 11β-HSD enzymes. The reaction direction of 11β-HSD1 is dictated by its association with hexose-6-phosphate dehydrogenase (H6PD), which couples glucose-6-phosphate oxidation to NADP reduction, generating NADPH co-factor to drive 11β-HSD1 reductase activity. 11β-HSD1 has attracted a lot of recent attention as a potential therapeutic target for metabolic disease, with inhibitors currently under clinical development. Overexpression of 11β-HSD1 in adipose tissue is associated with obesity in both humans and rodents and in transgenic mice, additionally causes hypertension and insulin resistance (reviewed in ). Conversely, inhibition of, or deficiency in 11β-HSD1 reduces hyperglycemia and improves insulin sensitivity in non-insulin dependent diabetes in humans and rodents. Selective inhibition of 11β-HSD1 also prevented progression of atherosclerosis in Apoe−/− mice and lowered levels of circulating MCP-1, a cytokine that recruits monocytes to sites of injury. It will be important to determine the extent to which these pro-inflammatory effects of 11β-HSD1 are due to its dysregulation in adipose tissue and possibly other tissues in metabolic disease.

11β-HSD1 is widely expressed, with highest expression in classical glucocorticoid target tissues. Given the crucial immunomodulatory actions of glucocorticoids and the strong association between inflammation and insulin resistance/metabolic disease, the role of 11β-HSD1 in the inflammatory response is of great interest. This area has been recently reviewed and the discussion here is restricted to recent developments and questions.

Like GR, 11β-HSD1 is widely expressed in immune cells, but its expression is highly dependent on the differentiation and activation state of the cell. Circulating leukocytes show little or no 11β-HSD1 expression, consistent with negligible 11β-HSD1 activity in monocytes and low levels in lymphocytes and neutrophils. However, following differentiation of monocytes to macrophages or dendritic cells, 11β-HSD1 activity is dramatically increased and is further increased with polarisation to “M1” pro-inflammatory macrophages compared to “M2” anti-inflammatory macrophages. Amplification of endogenous glucocorticoids by 11β-HSD1 may influence macrophage state as thioglycollate-elicited peritoneal macrophages from 11β-HSD1-deficient mice showed increased pro-inflammatory cytokine production following LPS stimulation in vitro, in the absence of added 11β-HSD1 substrate as well as in vivo. Interestingly, macrophage 11β-HSD1 is down-regulated following phagocytosis of apoptotic neutrophils; a pro-resolution process. The down-regulation of 11β-HSD1 may be part of this mechanism to terminate inflammation. In the absence of 11β-HSD1, mice are more sensitive to endotoxaemia, acute inflammation is more severe, and pro-resolution mechanisms may be delayed. We have recently found 11β-HSD1 expression and activity in mast cells, key initiators of acute inflammation and critical targets of the anti-inflammatory actions of glucocorticoids in allergy. Mast cells from 11β-HSD1-deficient mice are hypersensitive to degranulating stimuli, suggesting that endogenous glucocorticoid amplification via 11β-HSD1 restrains their activity. This may be analagous to dendritic cells where it has also been suggested that 11β-HSD1 activity, which is set at high levels in immature dendritic cells and decreases following CD40 activation (a signal that supports cytotoxic T cell differentiation ), may raise the threshold for dendritic cell-induced immune activation, by increasing glucocorticoid action within immature dendritic cells.

Within lymphoid cells, 11β-HSD1 activity is present at low levels but is increased following activation of CD4+ T cells through the T cell receptor or following polarisation into Th1 or Th2 cells, possibly enhancing the ability of endogenous glucocorticoids to suppress Th1 cytokines (in Th1 cells) as well as sparing or promoting Th2 cytokine production by Th2 cells. Thymocytes also express low levels of 11β-HSD1, which is markedly increased, in parallel with GR levels, by burn injury in mice, a strong stimulus to the HPA axis. The increase in 11β-HSD1 activity was associated with an increased rate of thymocyte apoptosis. The same may be true in human lymphocyte precursors. In a recent study in acute lymphoblastic leukaemia (ALL) patients, glucocorticoid treatment increased both 11β-HSD1 and GR mRNA levels in glucocorticoid-sensitive leukaemic cells, but decreased 11β-HSD1 mRNA levels in cells resistant to the pro-apoptotic effects of glucocorticoids. This combination of increased 11β-HSD1 and GR expression is likely to contribute very significantly to the increased glucocorticoid sensitivity of the leukaemic cells, though whether low 11β-HSD1 and GR expression is a cause or an effect of the glucocorticoid resistance in glucocorticoid-resistant leukaemia remains to be determined.

Of great interest is the relevance of 11β-HSD1 to human inflammatory disease. 11β-HSD1 expression is increased in a cell-specific manner by pro-inflammatory cytokines, particularly IL-1 and TNFα (reviewed, ) and at sites of inflammation. However, it may be decreased in others. Recent data have shown decreased 11β-HSD1 mRNA levels in lung in a mouse model of tuberculosis, where, similar to other inflammatory conditions, 11β-HSD1 shows a reciprocal regulation to 11β-HSD2. An even further level of complexity is revealed by the findings that in human rheumatoid arthritis, 11β-HSD1 is increased in synovial fibroblasts, whereas synovial macrophages express 11β-HSD2; suggesting a complex control over glucocorticoid availability within the rheumatic joint. 11β-HSD2 is not normally expressed in macrophages, nor is it expressed here during acute inflammation, at least in mice. However, other groups have also reported 11β-HSD2 expression in rheumatoid arthritis patients in synovial macrophages, immortalised B cells and peripheral blood mononuclear cells. Whether this is part of an adaptive response to inflammation or contributes to glucocorticoid resistance will be important to establish.

Finally, recent work is starting to elucidate the mechanisms that regulate 11β-HSD1 expression. Whilst the C/EBP family of transcription factors was implicated some years ago, recent data have shown the pivotal role of C/EBPβ in the adipocyte expression and tissue-specific regulation of 11β-HSD1, and importantly, in mediating the effects of pro-inflammatory mediators on transcription of the gene. C/EBPβ has also been implicated in the glucocorticoid-induction of 11β-HSD1 in adipose tissue, although this may be a tissue-specific mechanism. Given that C/EBPβ occupies a pivotal position in the integration of metabolic and inflammatory signals, is a critical component of some glucocorticoid responsive units (e.g., and ) and is also a glucocorticoid target gene itself, being regulated at both mRNA and post-translational levels by glucocorticoids in a tissue-specific manner, it will be extremely informative to unravel the associations between C/EBPβ, 11β-HSD1 and glucocorticoids in determination of immune cell differentiation and function.

Summary and conclusions

Many aspects of the anti-inflammatory actions of glucocorticoids have not been covered here. However, it is clear that the field is at an exciting stage. The next few years should provide a big step forward in our understanding of how these important hormones exert their effects, with concomitant advances in the clinical treatment of inflammatory disease.

References 229

  1. 1.

    Abbott A.N., Guidry T.V., Welsh K.J., Thomas A.M., Kling M.A., Hunter R.L., Actor J.K. 11β-Hydroxysteroid Dehydrogenases Are Regulated during the Pulmonary Granulomatous Response to the Mycobacterial Glycolipid Trehalose-6,6’-Dimycolate. Neuroimmunomodulation. 2009;16:147-154.

    Not in our library10.1159/000204227

  2. 2.

    Abraham S.M., Lawrence T., Kleiman A., Warden P., Medghalchi M., Tuckermann J., Saklatvala J., Clark A.R. Antiinflammatory effects of dexamethasone are partly dependent on induction of dual specificity phosphatase 1. J. Exp. Med. 2006;203:1883-1889.

    Not in our library10.1084/jem.20060336

  3. 3.

    Adams M., Meijer O.C., Wang J., Bhargava A., Pearce D. Homodimerization of the glucocorticoid receptor is not essential for response element binding: activation of the phenylethanolamine N-methyltransferase gene by dimerization-defective mutants. Mol. Endocrinol. 2003;17:2583-2592.

    Not in our library10.1210/me.2002-0305

  4. 4.

    Ahmed A., Saksena S., Sherlock M., Olliff S.P., Elias E., Stewart P.M. Induction of hepatic 11β-hydroxysteroid dehydrogenase type 1 in patients with alcoholic liver disease. Clin. Endocrinol. (Oxf). 2008;68:898-903.

    Not in our library10.1111/j.1365-2265.2007.03125.x

  5. 5.

    Alam T., An M.R., Mifflin R.C., Hsieh C.-C., Ge X., Papaconstantinou J. Trans-activation of the α1-acid glycoprotein gene acute phase responsive element by multiple isoforms of C/EBP and glucocorticoid receptor. J. Biol. Chem. 1993;268:15681-15688.

    Not in our library

  6. 6.

    Arai N., Masuzaki H., Tanaka T., Ishii T., Yasue S., Kobayashi N., Tomita T., Noguchi M., Kusakabe T., Fujikura J., Ebihara K., Hirata M., Hosoda K., Hayashi T., Sawai H., Minokoshi Y., Nakao K. Ceramide and adenosine 5’-monophosphate-activated protein kinase are two novel regulators of 11β-hydroxysteroid dehydrogenase type 1 expression and activity in cultured preadipocytes. Endocrinology. 2007;148:5268-5277.

    Not in our library10.1210/en.2007-0349

  7. 7.

    Ashwell J.D., Lu F.W., Vacchio M.S. Glucocorticoids in T cell development and function. Ann. Rev. Immunol. 2000;18:309-345.

    Not in our library10.1146/annurev.immunol.18.1.309

  8. 8.

    Atanasov A.G., Nashev L.G., Gelman L., Legeza B., Sack R., Portmann R., Odermatt A. Direct protein-protein interaction of 11β-hydroxysteroid dehydrogenase type 1 and hexose-6-phosphate dehydrogenase in the endoplasmic reticulum lumen. Biochim. Biophys. Acta. 2008;1783:1536-1543.

    Not in our library10.1016/j.bbamcr.2008.03.001

  9. 9.

    Auphan N., DiDonato J.A., Rosette C., Helmberg A., Karin M. Immunosupression by glucocorticoids: inhibition of NF-κB activity through induction of IκB synthesis. Science. 1995;270:286-290.

    Not in our library10.1126/science.270.5234.286

  10. 10.

    Ayroldi E., Riccardi C. Glucocorticoid-induced leucine zipper (GILZ): a new important mediator of glucocorticoid action. FASEB J. 2009;23:3649-3658.

    Not in our library10.1096/fj.09-134684

  11. 11.

    Barish G.D., Downes M., Alaynick W.A., Yu R.T., Ocampo C.B., Bookout A.L., Mangelsdorf D.J., Evans R.M. A Nuclear Receptor Atlas: macrophage activation. Mol. Endocrinol. 2005;19:2466-2477.

    Not in our library10.1210/me.2004-0529

  12. 12.

    Barnes P.J. Anti-inflammatory actions of glucocorticoids: molecular mechanisms. Clin. Sci. (Lond). 1998;94:557-572.

    Not in our library10.1042/cs0940557

  13. 13.

    Beato M., Chalepakis G., Schauer M., Slater E.P. DNA regulatory elements for steroid hormones. J. Steroid Biochem. 1989;32:737-748.

    Not in our library10.1016/0022-4731(89)90521-9

  14. 14.

    Beato M., Chavez S., Truss M. Transcriptional regulation by steroid hormones. Steroids. 1996;61:240-251.

    Not in our library10.1016/0039-128x(96)00030-x

  15. 15.

    Berg T., Didon L., Barton J., Andersson O., Nord M. Glucocorticoids increase C/EBPβ activity in the lung epithelium via phosphorylation. Biochem. Biophys. Res. Commun. 2005;334:638-645.

    Not in our library10.1016/j.bbrc.2005.06.146

  16. 16.

    Bertini R., Bianchi M., Ghezzi P. Adrenalectomy sensitizes mice to the lethal effects of Interleukin-1 and Tumor Necrosis Factor. J. Exp. Med. 1988;167:1708-1712.

    Not in our library10.1084/jem.167.5.1708

  17. 17.

    Besedovsky H.O., del Rey A. Immune-neuro-endocrine interactions: facts and hypotheses. Endocr. Rev. 1996;17:64-102.

    Not in our library10.1210/edrv-17-1-64

  18. 18.

    Bhattacharyya S., Brown D.E., Brewer J.A., Vogt S.K., Muglia L.J. Macrophage glucocorticoid receptors regulate Toll-like receptor-4-mediated inflammatory responses by selective inhibition of p38 MAP kinase. Blood. 2007;109:4313-4319.

    Not in our library10.1182/blood-2006-10-048215

  19. 19.

    Biddie S.C., Hager G.L. Glucocorticoid receptor dynamics and gene regulation. Stress. 2009;12:193-205.

    Not in our library10.1080/10253890802506409

  20. 20.

    Biggadike K., Bledsoe R.K., Coe D.M., Cooper T.W., House D., Iannone M.A., Macdonald S.J., Madauss K.P., McLay I.M., Shipley T.J., Taylor S.J., Tran T.B., Uings I.J., Weller V., Williams S.P. Design and X-ray crystal structures of high-potency nonsteroidal glucocorticoid agonists exploiting a novel binding site on the receptor. Proc. Natl. Acad. Sci. U.S.A. 2009;106:18114-18119.

    Not in our library10.1073/pnas.0909125106

  21. 21.

    Blind R.D., Garabedian M.J. Differential recruitment of glucocorticoid receptor phospho-isoforms to glucocorticoid-induced genes. J. Steroid Biochem. Mol. Biol. 2008;109:150-157.

    Not in our library10.1016/j.jsbmb.2008.01.002

  22. 22.

    Bommhardt U., Beyer M., Hunig T., Reichardt H.M. Molecular and cellular mechanisms of T cell development. Cell. Mol. Life Sci. 2004;61:263-280.

    Not in our library10.1007/s00018-003-3224-3

  23. 23.

    Boyle C.D., Kowalski T.J. 11β-hydroxysteroid dehydrogenase type 1 inhibitors: a review of recent patents. Expert Opin. Ther. Pat. 2009;19:801-825.

    Not in our library10.1517/13543770902967658

  24. 24.

    Brewer J.A., Kanagawa O., Sleckman B.P., Muglia L.J. Thymocyte apoptosis induced by T cell activation is mediated by glucocorticoids in vivo. J. Immunol. 2002;169:1837-1843.

    Not in our library10.4049/jimmunol.169.4.1837

  25. 25.

    Brewer J.A., Khor B., Vogt S.K., Muglia L.M., Fujiwara H., Haegele K.E., Sleckman B.P., Muglia L.J. T-cell glucocorticoid receptor is required to suppress COX-2-mediated lethal immune activation. Nat. Med. 2003;9:1318-1322.

    Not in our library10.1038/nm895

  26. 26.

    Cannarile L., Cuzzocrea S., Santucci L., Agostini M., Mazzon E., Esposito E., Muia C., Coppo M., Di Paola R., Riccardi C. Glucocorticoid-induced leucine zipper is protective in Th1-mediated models of colitis. Gastroenterology. 2009;136:530-541.

    Not in our library10.1053/j.gastro.2008.09.024

  27. 27.

    Cannarile L., Fallarino F., Agostini M., Cuzzocrea S., Mazzon E., Vacca C., Genovese T., Migliorati G., Ayroldi E., Riccardi C. Increased GILZ expression in transgenic mice up-regulates Th-2 lymphokines. Blood. 2006;107:1039-1047.

    Not in our library10.1182/blood-2005-05-2183

  28. 28.

    Chamorro S., Garcia-Vallejo J.J., Unger W.W., Fernandes R.J., Bruijns S.C., Laban S., Roep B.O., t Hart B.A., van Kooyk Y. TLR triggering on tolerogenic dendritic cells results in TLR2 up-regulation and a reduced proinflammatory immune program. J. Immunol. 2009;183:2984-2994.

    Not in our library10.4049/jimmunol.0801155

  29. 29.

    Chapman K.E., Coutinho A., Gray M., Gilmour J.S., Savill J.S., Seckl J.R. Local amplification of glucocorticoids by 11β-hydroxysteroid dehydrogenase type 1 and its role in the inflammatory response. Ann. N.Y. Acad. Sci. 2006;1088:265-273.

    Not in our library10.1196/annals.1366.030

  30. 30.

    Chapman K.E., Coutinho A.E., Gray M., Gilmour J.S., Savill J.S., Seckl J.R. The role and regulation of 11β-hydroxysteroid dehydrogenase type 1 in the inflammatory response. Mol. Cell. Endocrinol. 2009;301:123-131.

    Not in our library10.1016/j.mce.2008.09.031

  31. 31.

    Chapman K.E., Gilmour J.S., Coutinho A.E., Savill J.S., Seckl J.R. 11β-hydroxysteroid dehydrogenase type 1- a role in inflammation? Mol. Cell Endocrinol. 2006;248:3-8.

    Not in our library10.1016/j.mce.2005.11.036

  32. 32.

    Cho I.J., Woo N.R., Kim S.G. The identification of C/EBPβ as a transcription factor necessary for the induction of MAPK phosphatase-1 by toll-like receptor-4 ligand. Arch. Biochem. Biophys. 2008;479:88-96.

    Not in our library10.1016/j.abb.2008.08.007

  33. 33.

    Clark A.R. Anti-inflammatory functions of glucocorticoid-induced genes. Mol. Cell. Endocrinol. 2007;275:79-97.

    Not in our library10.1016/j.mce.2007.04.013

  34. 34.

    Clausen B.E., Burkhardt C., Reith W., Renkawitz R., Forster I. Conditional gene targeting in macrophages and granulocytes using LysMcre mice. Transgenic Res. 1999;8:265-277.

    Not in our library10.1023/a:1008942828960

  35. 35.

    Cohen N., Mouly E., Hamdi H., Maillot M.-C., Pallardy M., Godot V., Capel F., Balian A., Naveau S., Galanaud P., Lemoine F.M., Emilie D. GILZ expression in human dendritic cells redirects their maturation and prevents antigen-specific T lymphocyte response. Blood. 2006;107:2037-2044.

    Not in our library10.1182/blood-2005-07-2760

  36. 36.

    Cole T., Blendy J.A., Monaghan A.P., Kriegelstein K., Schmid W., Fantuzzi G., Hummler E., Unsicker K., Schütz G. Targeted disruption of the glucocorticoid receptor blocks adrenergic chromaffin cell development and severely retards lung maturation. Genes Dev. 1995;9:1608-1621.

    Not in our library10.1101/gad.9.13.1608

  37. 37.

    Cole T.J., Myles K., Purton J.F., Brereton P.S., Solomon N.M., Godfrey D.I., Funder J.W. GRKO mice express an aberrant dexamethasone-binding glucocorticoid receptor, but are profoundly glucocorticoid resistant. Mol. Cell. Endocrinol. 2001;173:193-202.

    Not in our library10.1016/s0303-7207(00)00407-x

  38. 38.

    Cooper M.S., Stewart P.M. 11β-Hydroxysteroid dehydrogenase type 1 and its role in the hypothalamus-pituitary-adrenal axis, metabolic syndrome, and inflammation. J. Clin. Endocrinol. Metab. 2009;(October (16)).

    Not in our library10.1210/jc.2009-1412

  39. 39.

    Couper K.N., Blount D.G., Riley E.M. IL-10: the master regulator of immunity to infection. J. Immunol. 2008;180:5771-5777.

    Not in our library10.4049/jimmunol.180.9.5771

  40. 40.

    Coutinho A.E., Gray M., Sawatzky D.A., Brownstein D., Gilmour J.S., Mullins J., Seckl J.R., Savill J.S., Chapman K.E. Deficiency in 11β-hydroxysteroid dehydrogenase type 1 results in a more rapid and severe inflammation. Abstracts of the 88th meeting of the American Endocrine Society. 2006;2-108.

    Not in our library

  41. 41.

    Croniger C., Trus M., Lysek-Stupp K., Cohen H., Liu Y., Darlington G.J., Poli V., Hanson R.W., Reshef L. Role of the isoforms of CCAAT/enhancer-binding protein in the initiation of phosphoenolpyruvate carboxykinase (GTP) gene transcription at birth. J. Biol. Chem. 1997;272:26306-26312.

    Not in our library10.1074/jbc.272.42.26306

  42. 42.

    Croxtall J.D., van Hal P.T., Choudhury Q., Gilroy D.W., Flower R.J. Different glucocorticoids vary in their genomic and non-genomic mechanism of action in A549 cells. Br. J. Pharmacol. 2002;135:511-519.

    Not in our library10.1038/sj.bjp.0704474

  43. 43.

    D’Acquisto F., Merghani A., Lecona E., Rosignoli G., Raza K., Buckley C.D., Flower R.J., Perretti M. Annexin-1 modulates T-cell activation and differentiation. Blood. 2007;109:1095-1102.

    Not in our library10.1182/blood-2006-05-022798

  44. 44.

    D’Acquisto F., Paschalidis N., Raza K., Buckley C.D., Flower R.J., Perretti M. Glucocorticoid treatment inhibits annexin-1 expression in rheumatoid arthritis CD4+ T cells. Rheumatology (Oxford). 2008;47:636-639.

    Not in our library10.1093/rheumatology/ken062

  45. 45.

    D’Acquisto F., Paschalidis N., Sampaio A.L., Merghani A., Flower R.J., Perretti M. Impaired T cell activation and increased Th2 lineage commitment in Annexin-1-deficient T cells. Eur. J. Immunol. 2007;37:3131-3142.

    Not in our library10.1002/eji.200636792

  46. 46.

    D’Elia M., Patenaude J., Bernier J. Regulation of glucocorticoid sensitivity in thymocytes from burn-injured mice. Am. J. Physiol. Endocrinol. Metab. 2009;296:E97-E104.

    Not in our library10.1152/ajpendo.90582.2008

  47. 47.

    De Bosscher K., Haegeman G. Latest perspectives on anti-inflammatory actions of glucocorticoids. Mol. Endocrinol. 2009;23:281-291.

    Not in our library10.1210/me.2008-0283

  48. 48.

    de Vries F., Pouwels S., Lammers J.W., Leufkens H.G., Bracke M., CooperF C., van Staa T.P. Use of inhaled and oral glucocorticoids, severity of inflammatory disease and risk of hip/femur fracture: a population-based case-control study. J. Intern. Med. 2007;261:170-177.

    Not in our library10.1111/j.1365-2796.2006.01754.x

  49. 49.

    Delfino D.V., Agostini M., Spinicelli S., Vacca C., Riccardi C. Inhibited cell death, NF-|B activity and increased IL-10 in TCR-triggered thymocytes of transgenic mice overexpressing the glucocorticoid-induced protein GILZ. Int. Immunopharmacol. 2006;6:1126-1134.

    Not in our library10.1016/j.intimp.2006.02.001

  50. 50.

    Du K., Ding J. Insulin Regulates TRB3 and Other Stress Responsive Gene Expression through Induction of C/EBPβ. Mol. Endocrinol. 2009;23:475-485.

    Not in our library10.1210/me.2008-0284

  51. 51.

    Ehrchen J., Steinmuller L., Barczyk K., Tenbrock K., Nacken W., Eisenacher M., Nordhues U., Sorg C., Sunderkotter C., Roth J. Glucocorticoids induce differentiation of a specifically activated, anti-inflammatory subtype of human monocytes. Blood. 2007;109:1265-1274.

    Not in our library10.1182/blood-2006-02-001115

  52. 52.

    Elmore S.W., Pratt J.K., Coghlan M.J., Mao Y., Green B.E., Anderson D.D., Stashko M.A., Lin C.W., Falls D., Nakane M., Miller L., Tyree C.M., Miner J.N., Lane B. Differentiation of in vitro transcriptional repression and activation profiles of selective glucocorticoid modulators. Bioorg. Med. Chem. Lett. 2004;14:1721-1727.

    Not in our library10.1016/j.bmcl.2004.01.044

  53. 53.

    Ergang P., Leden P., Bryndova J., Zbankova S., Miksik I., Kment M., Pacha J. Glucocorticoid availability in colonic inflammation of rat. Dig. Dis. Sci. 2007;53:2160-2167.

    Not in our library10.1007/s10620-007-0125-6

  54. 54.

    Fadok V.A., Bratton D.L., Konowal A., Freed P.W., Westcott J.Y., Henson P.M. Macrophages that have ingested apoptotic cells in vitro inhibit proinflammatory cytokine production through autocrine/paracrine mechanisms involving TGF-βPGE2, and PAF. J. Clin. Invest. 1998;101:890-898.

    Not in our library10.1172/jci1112

  55. 55.

    Finotto S., Krieglstein K., Schober A., Deimling F., Lindner K., Bruhl B., Beier K., Metz J., GarciaArraras J.E., RoigLopez J.L., Monaghan P., Schmid W., Cole T.J., Kellendonk C., Tronche F., Schutz G., Unsicker K. Analysis of mice carrying targeted mutations of the glucocorticoid receptor gene argues against an essential role of glucocorticoid signalling for generating adrenal chromaffin cells. Development. 1999;126:2935-2944.

    Not in our library10.1242/dev.126.13.2935

  56. 56.

    Fiore C., Nardi A., Dalla Valle L., Pellati D., Krozowski Z., Colombo L., Armanini D. Identification of the 11β-hydroxysteroid dehydrogenase type 1 mRNA and protein in human mononuclear leukocytes. Exp. Clin. Endocrinol. Diabetes. 2009;117:514-518.

    Not in our library10.1055/s-0028-1105924

  57. 57.

    Frank M.G., Miguel Z.D., Watkins L.R., Maier S.F. Prior exposure to glucocorticoids sensitizes the neuroinflammatory and peripheral inflammatory responses to E. coli lipopolysaccharide. Brain Behav. Immun. 2010;24:19-30.

    Not in our library10.1016/j.bbi.2009.07.008

  58. 58.

    Freeman L., Hewison M., Hughes S.V., Evans K.N., Hardie D., Means T.K., Chakraverty R. Expression of 11β-hydroxysteroid dehydrogenase type 1 permits regulation of glucocorticoid bioavailability by human dendritic cells. Blood. 2005;106:2042-2049.

    Not in our library10.1182/blood-2005-01-0186

  59. 59.

    Funder J.W. Glucocorticoid and mineralocorticoid receptors: Biology and clinical relevance. Annu. Rev. Med. 1997;48:231-240.

    Not in our library10.1146/annurev.med.48.1.231

  60. 60.

    Giles K.M., Ross K., Rossi A.G., Hotchin N.A., Haslett C., Dransfield I. Glucocorticoid augmentation of macrophage capacity for phagocytosis of apoptotic cells is associated with reduced p130Cas expression, loss of paxillin/pyk2 phosphorylation, and high levels of active Rac. J. Immunol. 2001;167:976-986.

    Not in our library10.4049/jimmunol.167.2.976

  61. 61.

    Gilmour J.S., Coutinho A.E., Cailhier J.F., Man T.Y., Clay M., Thomas G., Harris H.J., Mullins J.J., Seckl J.R., Savill J.S., Chapman K.E. Local amplification of glucocorticoids by 11β-hydroxysteroid dehydrogenase type 1 promotes macrophage phagocytosis of apoptotic leukocytes. J. Immunol. 2006;176:7605-7611.

    Not in our library10.4049/jimmunol.176.12.7605

  62. 62.

    Gilroy D.W. The endogenous control of acute inflammation - from onset to resolution. Drug Discov. Today: Therap. Strategies. 2004;1:313.

    Not in our library

  63. 63.

    Godfrey D.I., Purton J.F., Boyd R.L., Cole T.J. Glucocorticoids and the thymus: the view from the middle of the road. Trends Immunol. 2001;22:243.

    Not in our library10.1016/s1471-4906(01)01916-0

  64. 64.

    Gotoh T., Chowdhury S., Takiguchi M., Mori M. The glucocorticoid-responsive gene cascade: activation of the rat arginase gene through induction of C/EBPβ. J. Biol. Chem. 1997;272:3694-3698.

    Not in our library10.1074/jbc.272.6.3694

  65. 65.

    Goulding N.J., Godolphin J.L., Sampson M.B., Maddison P.J., Flower R.J. Hydrocortisone induces lipocortin 1 production by peripheral blood mononuclear cells in vivo in man. Biochem. Soc. Trans. 1990;18:306-307.

    Not in our library10.1042/bst0180306

  66. 66.

    Gout J., Tirard J., Thevenon C., Riou J.P., Begeot M., Naville D. CCAAT/enhancer-binding proteins (C/EBPs) regulate the basal and cAMP-induced transcription of the human 11β-hydroxysteroid dehydrogenase encoding gene in adipose cells. Biochimie. 2006;88:1115-1124.

    Not in our library10.1016/j.biochi.2006.05.020

  67. 67.

    Grange T., Cappabianca L., Flavin M., Sassi H., Thomassin H. In vivo analysis of the model tyrosine aminotransferase gene reveals multiple sequential steps in glucocorticoid receptor action. Oncogene. 2001;20:3028-3038.

    Not in our library10.1038/sj.onc.1204327

  68. 68.

    Grange T., Roux J., Rigaud G., Pictet R. Two remote glucocorticoid responsive units interact cooperatively to promote glucocorticoid induction of rat tyrosine aminotransferase gene expression. Nucl. Acids Res. 1989;17:8695-8709.

    Not in our library10.1093/nar/17.21.8695

  69. 69.

    Grange T., Roux J., Rigaud G., Pictet R. Cell-type specific activity of two glucocorticoid responsive units of rat tyrosine aminotransferase gene is associated with multiple binding sites for C/EBP and a novel liver-specific nuclear factor. Nucl. Acids Res. 1991;19:131-139.

    Not in our library10.1093/nar/19.1.131

  70. 70.

    Haas C.S., Creighton C.J., Pi X., Maine I., Koch A.E., Haines G.K., Ling S., Chinnaiyan A.M., Holoshitz J. Identification of genes modulated in rheumatoid arthritis using complementary DNA microarray analysis of lymphoblastoid B cell lines from disease-discordant monozygotic twins. Arthritis Rheum. 2006;54:2047-2060.

    Not in our library10.1002/art.21953

  71. 71.

    Hager G.L., Nagaich A.K., Johnson T.A., Walker D.A., John S. Dynamics of nuclear receptor movement and transcription. Biochim. Biophys. Acta. 2004;1677:46-51.

    Not in our library10.1016/j.bbaexp.2003.09.016

  72. 72.

    Hamdi H., Godot V., Maillot M.C., Prejean M.V., Cohen N., Krzysiek R., Lemoine F.M., Zou W., Emilie D. Induction of antigen-specific regulatory T lymphocytes by human dendritic cells expressing the glucocorticoid-induced leucine zipper. Blood. 2007;110:211-219.

    Not in our library10.1182/blood-2007-08-107896

  73. 73.

    Hammer M., Mages J., Dietrich H., Servatius A., Howells N., Cato A.C., Lang R. Dual specificity phosphatase 1 (DUSP1) regulates a subset of LPS-induced genes and protects mice from lethal endotoxin shock. J. Exp. Med. 2006;203:15-20.

    Not in our library10.1084/jem.20051753

  74. 74.

    Hannon R., Croxtall J.D., Getting S.J., Roviezzo F., Yona S., Paul-Clark M.J., Gavins F.N., Perretti M., Morris J.F., Buckingham J.C., Flower R.J. Aberrant inflammation and resistance to glucocorticoids in annexin 1−/− mouse. FASEB J. 2003;17:253-255.

    Not in our library10.1096/fj.02-0239fje

  75. 75.

    Härd T., Kellenbach E., Boelens R., Maler B.A., Dahlman K., Freedman L.P., Carlstedt-Duke J., Yamamoto K.R., Gustafsson J.-Å. Solution structure of the glucocorticoid receptor DNA-binding domain. Science. 1990;249:157-160.

    Not in our library10.1126/science.2115209

  76. 76.

    Hardy R.S., Rabbitt E.H., Filer A., Emery P., Hewison M., Stewart P.M., Gittoes N., Buckley C.D., Raza K., Cooper M.S. Local and systemic glucocorticoid metabolism in inflammatory arthritis. Ann. Rheum. Dis. 2008;67:1204-1210.

    Not in our library10.1136/ard.2008.090662

  77. 77.

    Harizi H., Mormede P., Corcuff J.B. Inter-strain differences in glucocorticoid and mineralocorticoid effects on macrophage and lymphocyte functions in mice. J. Neuroimmunol. 2008;204:38-42.

    Not in our library10.1016/j.jneuroim.2008.08.004

  78. 78.

    Haslett C., Lee A., Savill J.S., Meagher L., Whyte M.K. Apoptosis (programmed cell death) and functional changes in aging neutrophils: modulation by inflammatory mediators. Chest. 1991;99:6S.

    Not in our library

  79. 79.

    Hawes A.S., Richardson R.P., Antonacci A.C., Calvano S.E. Chronic pathophysiologic elevation of corticosterone after thermal injury or thermal injury and burn wound infection adversely affects body mass, lymphocyte numbers, and outcome. J. Burn Care Rehabil. 1995;16:1-15.

    Not in our library10.1097/00004630-199501000-00002

  80. 80.

    Hawrylowicz C.M. Regulatory T cells and IL-10 in allergic inflammation. J. Exp. Med. 2005;202:1459-1463.

    Not in our library10.1084/jem.20052211

  81. 81.

    Heasman S.J., Giles K.M., Ward C., Rossi A.G., Haslett C., Dransfield I. Glucocorticoid-mediated regulation of granulocyte apoptosis and macrophage phagocytosis of apoptotic cells: implications for the resolution of inflammation. J. Endocrinol. 2003;178:29-36.

    Not in our library10.1677/joe.0.1780029

  82. 82.

    Heck S., Bender K., Kullmann M., Gottlicher M., Herrlich P., Cato A.C. IκBα-independent downregulation of NF-κB activity by glucocorticoid receptor. EMBO J. 1997;16:4698-4707.

    Not in our library10.1093/emboj/16.15.4698

  83. 83.

    Heck S., Kullmann M., Gast A., Ponta H., Rahmsdorf H.J., Herrlich P., Cato A.C.B. A distinct modulating domain in glucocorticoid receptor monomers in the repression of activity of the transcription factor AP-1. EMBO J. 1994;13:4087-4095.

    Not in our library10.1002/j.1460-2075.1994.tb06726.x

  84. 84.

    Hennebold J.D., Ryu S.Y., Mu H.H., Galbraith A., Daynes R.A. 11β-hydroxysteroid dehydrogenase modulation of glucocorticoid activities in lymphoid organs. Am. J. Physiol. 1996;270:R1296-1306.

    Not in our library10.1152/ajpregu.1996.270.6.r1296

  85. 85.

    Hermanowski-Vosatka A., Balkovec J.M., Cheng K., Chen H.Y., Hernandez M., Koo G.C., Le Grand C.B., Li Z., Metzger J.M., Mundt S.S., Noonan H., Nunes C.N., Olson S.H., Pikounis B., Ren N., Robertson N., Schaeffer J.M., Shah K., Springer M.S., Strack A.M., Strowski M., Wu K., Wu T., Xiao J., Zhang B.B., Wright S.D., Thieringer R. 11®-HSD1 inhibition ameliorates metabolic syndrome and prevents progression of atherosclerosis in mice. J. Exp. Med. 2005;202:517-527.

    Not in our library10.1084/jem.20050119

  86. 86.

    Herold M.J., McPherson K.G., Reichardt H.M. Glucocorticoids in T cell apoptosis and function. Cell. Mol. Life Sci. 2006;63:60-72.

    Not in our library10.1007/s00018-005-5390-y

  87. 87.

    Hollenberg S.M., Weinberger C., Ong E.S., Cerelli G., Oro A., Lebo R., Thompson E.B., Rosenfeld M.G., Evans R.M. Primary structure and expression of a functional human glucocorticoid receptor cDNA. Nature. 1985;318:635-641.

    Not in our library10.1038/318635a0

  88. 88.

    Horie-Inoue K., Takayama K., Bono H.U., Ouchi Y., Okazaki Y., Inoue S. Identification of novel steroid target genes through the combination of bioinformatics and functional analysis of hormone response elements. Biochem. Biophys. Res. Commun. 2006;339:99-106.

    Not in our library10.1016/j.bbrc.2005.10.188

  89. 89.

    Hu B., Ullenbruch M.R., Jin H., Gharaee-Kermani M., Phan S.H. An essential role for CCAAT/enhancer binding protein β in bleomycin-induced pulmonary fibrosis. J. Pathol. 2007;211:455-462.

    Not in our library10.1002/path.2119

  90. 90.

    Huggins A., Paschalidis N., Flower R.J., Perretti M., D’Acquisto F. Annexin-1-deficient dendritic cells acquire a mature phenotype during differentiation. Faseb J. 2009;23:985-996.

    Not in our library10.1096/fj.08-119040

  91. 91.

    Ignatova I.D., Kostadinova R.M., Goldring C.E., Nawrocki A.R., Frey F.J., Frey B.M. Tumor necrosis factor-〈 upregulates 11β-hydroxysteroid dehydrogenase type 1 expression by CCAAT/enhancer binding protein-β in HepG2 cells. Am. J. Physiol. Endocrinol. Metab. 2009;296:E367-377.

    Not in our library10.1152/ajpendo.90531.2008

  92. 92.

    Imai E., Stromstedt P.E., Quinn P.G., Carlstedtduke J., Gustafsson J.A., Granner D.K. Characterization of a complex glucocorticoid response unit in the phosphoenolpyruvate carboxykinase gene. Mol. Cell. Biol. 1990;10:4712-4719.

    Not in our library10.1128/mcb.10.9.4712-4719.1990

  93. 93.

    Ito Y., Daitoku H., Fukamizu A. Foxo1 increases pro-inflammatory gene expression by inducing C/EBPβ in TNFα-treated adipocytes. Biochem. Biophys. Res. Commun. 2009;378:290-295.

    Not in our library10.1016/j.bbrc.2008.11.043

  94. 94.

    Jaffe H.L. The influence of the suprarenal gland on the thymus. J. Exp. Med., XL. 1924;325-343.

    Not in our library10.1084/jem.40.3.325

  95. 95.

    Jang C., Obeyesekere V.R., Alford F.P., Inder W.J. Skeletal muscle 11β-hydroxysteroid dehydrogenase type 1 activity is upregulated following elective abdominal surgery. Eur. J. Endocrinol. 2009;160:249-255.

    Not in our library10.1530/eje-08-0619

  96. 96.

    Johansson Haque K., Palanichamy E., Okret S. Stimulation of MAPK-phospatase 1 (MKP-1) gene expression by glucocorticoids occurs through a tethering mechanism involving C/EBP. J. Mol. Endocrinol. 2008;41:239-249.

    Not in our library10.1677/jme-08-0015

  97. 97.

    John S., Johnson T.A., Sung M.H., Biddie S.C., Trump S., Koch-Paiz C.A., Davis S.R., Walker R., Meltzer P.S., Hager G.L. Kinetic complexity of the global response to glucocorticoid receptor action. Endocrinology. 2009;150:1766-1774.

    Not in our library10.1210/en.2008-0863

  98. 98.

    John S., Sabo P.J., Johnson T.A., Sung M.H., Biddie S.C., Lightman S.L., Voss T.C., Davis S.R., Meltzer P.S., Stamatoyannopoulos J.A., Hager G.L. Interaction of the glucocorticoid receptor with the chromatin landscape. Mol. Cell. 2008;29:611-624.

    Not in our library10.1016/j.molcel.2008.02.010

  99. 99.

    Jonat C., Rahmsdorf H.J., Park K.K., Cato A.C.B., Gebel S., Ponta H., Herrlich P. Antitumor promotion and antiinflammation: down-modulation of AP-1 (Fos Jun) activity by glucocorticoid hormone. Cell. 1990;62:1189-1204.

    Not in our library10.1016/0092-8674(90)90395-u

  100. 100.

    Jondal M., Pazirandeh A., Okret S. Different roles for glucocorticoids in thymocyte homeostasis? Trends Immunol. 2004;25:595-600.

    Not in our library10.1016/j.it.2004.09.003

  101. 101.

    Kardon T., Senesi S., Marcolongo P., Legeza B., Banhegyi G., Mandl J., Fulceri R., Benedetti A. Maintenance of luminal NADPH in the endoplasmic reticulum promotes the survival of human neutrophil granulocytes. FEBS Lett. 2008;582:1809-1815.

    Not in our library10.1016/j.febslet.2008.04.045

  102. 102.

    Karin M. New twists in gene regulation by glucocorticoid receptor: Is DNA binding dispensable? Cell. 1998;93:487-490.

    Not in our library10.1016/s0092-8674(00)81177-0

  103. 103.

    Kassel O., Cato A.C. Mast cells as targets for glucocorticoids in the treatment of allergic disorders. Ernst Schering Res. Found Workshop. 2002;153-176.

    Not in our library10.1007/978-3-662-04660-9_10

  104. 104.

    Kimura T., Chowdhury S., Tanaka T., Shimizu A., Iwase K., Oyadomari S., Gotoh T., Matsuzaki H., Mori M., Akira S., Takiguchi M. CCAAT/enhancer-binding protein β is required for activation of genes for ornithine cycle enzymes by glucocorticoids and glucagon in primary- cultured hepatocytes. FEBS Lett. 2001;494:105-111.

    Not in our library10.1016/s0014-5793(01)02320-1

  105. 105.

    King L.B., Vacchio M.S., Dixon K., Hunziker R., Margulies D.H., Ashwell J.D. A targeted glucocorticoid receptor antisense transgene increases thymocyte apoptosis and alters thymocyte development. Immunity. 1995;3:647-656.

    Not in our library10.1016/1074-7613(95)90135-3

  106. 106.

    Kizaki T., Ookawara T., Oh-Ishi S., Itoh Y., Iwabuchi K., Onoe K., Day N.K., Good R.A., Ohno H. An increase in basal glucocorticoid concentration with age induces suppressor macrophages with high-density Fc gamma RII/III. Immunology. 1998;93:409-414.

    Not in our library10.1046/j.1365-2567.1998.00433.x

  107. 107.

    Kleiman A., Tuckermann J.P. Glucocorticoid receptor action in beneficial and side effects of steroid therapy: lessons from conditional knockout mice. Mol. Cell. Endocrinol. 2007;275:98-108.

    Not in our library10.1016/j.mce.2007.05.009

  108. 108.

    Koldzic-Zivanovic N., Tu H., Juelich T.L., Rady P.L., Tyring S.K., Hudnall S.D., Smith E.M., Hughes T.K. Regulation of adrenal glucocorticoid synthesis by interleukin-10: a preponderance of IL-10 receptor in the adrenal zona fasciculata. Brain Behav. Immun. 2006;20:460-468.

    Not in our library10.1016/j.bbi.2005.09.003

  109. 109.

    Kuhn R., Lohler J., Rennick D., Rajewsky K., Muller W. Interleukin-10-deficient mice develop chronic enterocolitis. Cell. 1993;75:263-274.

    Not in our library10.1016/0092-8674(93)80068-p

  110. 110.

    Lacy-Hulbert A., Smith A.M., Tissire H., Barry M., Crowley D., Bronson R.T., Roes J.T., Savill J.S., Hynes R.O. Ulcerative colitis and autoimmunity induced by loss of myeloid alphav integrins. Proc. Natl. Acad. Sci. U.S.A. 2007;104:15823-15828.

    Not in our library10.1073/pnas.0707421104

  111. 111.

    Lefstin J.A., Yamamoto K.R. Allosteric effects of DNA on transcriptional regulators. Nature. 1998;392:885-888.

    Not in our library10.1038/31860

  112. 112.

    Lightman S.L. The neuroendocrinology of stress: a never ending story. J. Neuroendocrinol. 2008;20:880-884.

    Not in our library10.1111/j.1365-2826.2008.01711.x

  113. 113.

    Lim H.Y., Muller N., Herold M.J., van den Brandt J., Reichardt H.M. Glucocorticoids exert opposing effects on macrophage function dependent on their concentration. Immunology. 2007;122:47-53.

    Not in our library10.1111/j.1365-2567.2007.02611.x

  114. 114.

    Limbourg F.P., Huang Z., Plumier J.C., Simoncini T., Fujioka M., Tuckermann J., Schutz G., Moskowitz M.A., Liao J.K. Rapid nontranscriptional activation of endothelial nitric oxide synthase mediates increased cerebral blood flow and stroke protection by corticosteroids. J. Clin. Invest. 2002;110:1729-1738.

    Not in our library10.1172/jci15481

  115. 115.

    Lu F.W., Yasutomo K., Goodman G.B., McHeyzer-Williams L.J., McHeyzer-Williams M.G., Germain R.N., Ashwell J.D. Thymocyte resistance to glucocorticoids leads to antigen-specific unresponsiveness due to “holes” in the T cell repertoire. Immunity. 2000;12:183-192.

    Not in our library10.1016/s1074-7613(00)80171-5

  116. 116.

    Luisi B.F., Xu W.X., Otwinowski Z., Freedman L.P., Yamamoto K.R., Sigler P.B. Crystallographic analysis of the interaction of the glucocorticoid receptor With DNA. Nature. 1991;352:497-505.

    Not in our library10.1038/352497a0

  117. 117.

    Luther C., Adamopoulou E., Stoeckle C., Brucklacher-Waldert V., Rosenkranz D., Stoltze L., Lauer S., Poeschel S., Melms A., Tolosa E. Prednisolone treatment induces tolerogenic dendritic cells and a regulatory milieu in myasthenia gravis patients. J. Immunol. 2009;183:841-848.

    Not in our library10.4049/jimmunol.0802046

  118. 118.

    Madauss K.P., Bledsoe R.K., McLay I., Stewart E.L., Uings I.J., Weingarten G., Williams S.P. The first X-ray crystal structure of the glucocorticoid receptor bound to a non-steroidal agonist. Bioorg. Med. Chem. Lett. 2008;18:6097-6099.

    Not in our library10.1016/j.bmcl.2008.10.021

  119. 119.

    Maderna P., Yona S., Perretti M., Godson C. Modulation of phagocytosis of apoptotic neutrophils by supernatant from dexamethasone-treated macrophages and annexin-derived peptide Ac(2-26). J. Immunol. 2005;174:3727-3733.

    Not in our library10.4049/jimmunol.174.6.3727

  120. 120.

    Maier J.V., Brema S., Tuckermann J., Herzer U., Klein M., Stassen M., Moorthy A., Cato A.C. Dual specificity phosphatase 1 knockout mice show enhanced susceptibility to anaphylaxis but are sensitive to glucocorticoids. Mol. Endocrinol. 2007;21:2663-2671.

    Not in our library10.1210/me.2007-0067

  121. 121.

    Martinez F.O., Gordon S., Locati M., Mantovani A. Transcriptional profiling of the human monocyte-to-macrophage differentiation and polarization: new molecules and patterns of gene expression. J. Immunol. 2006;177:7303-7311.

    Not in our library10.4049/jimmunol.177.10.7303

  122. 122.

    McColl A., Bournazos S., Franz S., Perretti M., Morgan B.P., Haslett C., Dransfield I. Glucocorticoids induce protein S-dependent phagocytosis of apoptotic neutrophils by human macrophages. J. Immunol. 2009;183:2167-2175.

    Not in our library10.4049/jimmunol.0803503

  123. 123.

    McColl A., Michlewska S., Dransfield I., Rossi A.G. Effects of glucocorticoids on apoptosis and clearance of apoptotic cells. Sci. W. J. 2007;7:1165-1181.

    Not in our library10.1100/tsw.2007.224

  124. 124.

    McEwen B.S., Biron C.A., Brunson K.W., Bulloch K., Chambers W.H., Dhabhar F.S., Goldfarb R.H., Kitson R.P., Miller A.H., Spencer R.L., Weiss J.M. The role of adrenocorticoids as modulators of immune function in health and disease: neural, endocrine and immune interactions. Brain Res. Rev. 1997;23:79-133.

    Not in our library10.1016/s0165-0173(96)00012-4

  125. 125.

    McKay L.I., Cidlowski J.A. Molecular control of immune/inflammatory responses: Interactions between NF-κB and steroid receptor-signaling pathways. Endocrinol. Rev. 1999;20:435-459.

    Not in our library10.1210/edrv.20.4.0375

  126. 126.

    McKnight S.L. McBindall—a better name for CCAAT/enhancer binding proteins? Cell. 2001;107:259-261.

    Not in our library10.1016/s0092-8674(01)00543-8

  127. 127.

    Meijsing S.H., Pufall M.A., So A.Y., Bates D.L., Chen L., Yamamoto K.R. DNA binding site sequence directs glucocorticoid receptor structure and activity. Science. 2009;324:407-410.

    Not in our library10.1126/science.1164265

  128. 128.

    Miesfeld R., Rusconi S., Godowski P.J., Maler B.A., Okret S., Wikström A.C., Gustafsson J.-Å., Yamamoto K.R. Genetic complementation of a glucocorticoid receptor deficiency by expression of cloned receptor cDNA. Cell. 1986;46:389-399.

    Not in our library10.1016/0092-8674(86)90659-8

  129. 129.

    Miller A.H., Spencer R.L., Stein M., McEwen B.S. Adrenal steroid receptor binding in spleen and thymus after stress or dexamethasone. Am. J. Physiol. 1990;259:E405-E412.

    Not in our library10.1152/ajpendo.1990.259.3.e405

  130. 130.

    Millward C.A., Heaney J.D., Sinasac D.S., Chu E.C., Bederman I.R., Gilge D.A., Previs S.F., Croniger C.M. Mice with a deletion in the gene for CCAAT/enhancer-binding protein β are protected against diet-induced obesity. Diabetes. 2007;56:161-167.

    Not in our library10.2337/db06-0310

  131. 131.

    Mozo L., Suarez A., Gutierrez C. Glucocorticoids up-regulate constitutive interleukin-10 production by human monocytes. Clin. Exp. Allergy. 2004;34:406-412.

    Not in our library10.1111/j.1365-2222.2004.01824.x

  132. 132.

    Munck A., Guyre P.M., Holbrook N.J. Physiological functions of glucocorticoids in stress and their relationship to pharmacological actions. Endocrinol. Rev. 1984;5:25-44.

    Not in our library10.1210/edrv-5-1-25

  133. 133.

    Muzikar K.A., Nickols N.G., Dervan P.B. Repression of DNA-binding dependent glucocorticoid receptor-mediated gene expression. Proc. Natl. Acad. Sci. U.S.A. 2009;106:16598-16603.

    Not in our library10.1073/pnas.0909192106

  134. 134.

    Necela B.M., Cidlowski J.A. Mechanisms of glucocorticoid receptor action in noninflammatory and inflammatory cells. Proc. Am. Thorac. Soc. 2004;1:239-246.

    Not in our library10.1513/pats.200402-005ms

  135. 135.

    Nerlov C. The C/EBP family of transcription factors: a paradigm for interaction between gene expression and proliferation control. Trends Cell Biol. 2007;17:318-324.

    Not in our library10.1016/j.tcb.2007.07.004

  136. 136.

    Newton R., Holden N.S. Separating transrepression and transactivation: a distressing divorce for the glucocorticoid receptor? Mol. Pharmacol. 2007;72:799-809.

    Not in our library10.1124/mol.107.038794

  137. 137.

    O'Sullivan B.J., Thomas R. CD40 Ligation conditions dendritic cell antigen-presenting function through sustained activation of NF-κB. J. Immunol. 2002;168:5491-5498.

    Not in our library10.4049/jimmunol.168.11.5491

  138. 138.

    Olsen N., Sokka T., Seehorn C.L., Kraft B., Maas K., Moore J., Aune T.M. A gene expression signature for recent onset rheumatoid arthritis in peripheral blood mononuclear cells. Ann. Rheum. Dis. 2004;63:1387-1392.

    Not in our library10.1136/ard.2003.017194

  139. 139.

    Payne V.A., Au W.S., Gray S.L., Nora E.D., Rahman S.M., Sanders R., Hadaschik D., Friedman J.E., O’Rahilly S., Rochford J.J. Sequential regulation of diacylglycerol acyltransferase 2 expression by CAAT/enhancer-binding protein beta (C/EBPβ) and C/EBPα during adipogenesis. J. Biol. Chem. 2007;282:21005-21014.

    Not in our library10.1074/jbc.m702871200

  140. 140.

    Payvar F., Defranco D., Firestone G.L., Edgar B., Wrange O., Okret S., Gustafsson J.A., Yamamoto K.R. Sequence-specific binding of glucocorticoid receptor to MTV DNA at sites within and upstream of the transcribed region. Cell. 1983;35:381-392.

    Not in our library10.1016/0092-8674(83)90171-x

  141. 141.

    Pazirandeh A., Jondal M., Okret S. Conditional expression of a glucocorticoid receptor transgene in thymocytes reveals a role for thymic-derived glucocorticoids in thymopoiesis in vivo. Endocrinology. 2005;146:2501-2507.

    Not in our library10.1210/en.2004-0943

  142. 142.

    Pazirandeh A., Xue Y., Prestegaard T., Jondal M., Okret S. Effects of altered glucocorticoid sensitivity in the T-cell lineage on thymocyte and T-cell homeostasis. FASEB J. 2002;16:727-729.

    Not in our library10.1096/fj.01-0891fje

  143. 143.

    Pearce D., Yamamoto K.R. Mineralocorticoid and glucocorticoid receptor activities distinguished by nonreceptor factors at a composite response element. Science. 1993;259:1161-1165.

    Not in our library10.1126/science.8382376

  144. 144.

    Penner G., Gang G., Sun X., Wray C., Hasselgren P.O. C/EBP DNA-binding activity is upregulated by a glucocorticoid-dependent mechanism in septic muscle. Am. J. Physiol. Regul. Integr. Comp. Physiol. 2002;282:R439-444.

    Not in our library10.1152/ajpregu.00512.2001

  145. 145.

    Pepin M.-C., Pothier F., Barden N. Impaired type II glucocorticoid receptor function in mice bearing antisense RNA transgene. Nature. 1992;355:725-728.

    Not in our library10.1038/355725a0

  146. 146.

    Perretti M., Ahluwalia A. The microcirculation and inflammation: site of action for glucocorticoids. Microcirculation. 2000;7:147-161.

    Not in our library

  147. 147.

    Perretti M., D’Acquisto F. Annexin A1 and glucocorticoids as effectors of the resolution of inflammation. Nat. Rev. Immunol. 2009;9:62-70.

    Not in our library10.1038/nri2470

  148. 148.

    Planey S.L., Litwack G. Glucocorticoid-induced apoptosis in lymphocytes. Biochem. Biophys. Res. Commun. 2000;279:307-312.

    Not in our library10.1006/bbrc.2000.3922

  149. 149.

    Purton J.F., Boyd R.L., Cole T.J., Godfrey D.I. Intrathymic T cell development and selection proceeds normally in the absence of glucocorticoid receptor signaling. Immunity. 2000;13:179-186.

    Not in our library10.1016/s1074-7613(00)00018-2

  150. 150.

    Purton J.F., Monk J.A., Liddicoat D.R., Kyparissoudis K., Sakkal S., Richardson S.J., Godfrey D.I., Cole T.J. Expression of the glucocorticoid receptor from the 1A promoter correlates with T lymphocyte sensitivity to glucocorticoid-induced cell death. J. Immunol. 2004;173:3816-3824.

    Not in our library10.4049/jimmunol.173.6.3816

  151. 151.

    Purton J.F., Zhan Y., Liddicoat D.R., Hardy C.L., Lew A.M., Cole T.J., Godfrey D.I. Glucocorticoid receptor deficient thymic and peripheral T cells develop normally in adult mice. Eur. J. Immunol. 2002;32:3546-3555.

    Not in our library10.1002/1521-4141(200212)32:12<3546::aid-immu3546>3.0.co;2-s

  152. 152.

    Rea D., van Kooten C., van Meijgaarden K.E., Ottenhoff T.H., Melief C.J., Offringa R. Glucocorticoids transform CD40-triggering of dendritic cells into an alternative activation pathway resulting in antigen-presenting cells that secrete IL-10. Blood. 2000;95:3162-3167.

    Not in our library

  153. 153.

    Reddy T.E., Pauli F., Sprouse R.O., Neff N.F., Newberry K.M., Garabedian M.J., Myers R.M. Genomic determination of the glucocorticoid response reveals unexpected mechanisms of gene regulation. Genome Res. 2009;19:2163-2171.

    Not in our library10.1101/gr.097022.109

  154. 154.

    Reichardt H.M., Kaestner K.H., Tuckermann J., Kretz O., Wessely O., Bock R., Gass P., Schmid W., Herrlich P., Angel P., Schütz G. DNA binding of the glucocorticoid receptor is not essential for survival. Cell. 1998;93:531-541.

    Not in our library10.1016/s0092-8674(00)81183-6

  155. 155.

    Reichardt H.M., Tuckermann J.P., Gottlicher M., Vujic M., Weih F., Angel P., Herrlich P., Schutz G. Repression of inflammatory responses in the absence of DNA binding by the glucocorticoid receptor. EMBO J. 2001;20:7168-7173.

    Not in our library10.1093/emboj/20.24.7168

  156. 156.

    Reichardt H.M., Umland T., Bauer A., Kretz O., Schütz G. Mice with an increased glucocorticoid receptor gene dosage show enhanced resistance to stress and endotoxic shock. Mol. Cell. Biol. 2000;20:9009-9017.

    Not in our library10.1128/mcb.20.23.9009-9017.2000

  157. 157.

    Rennick D., Davidson N., Berg D. Interleukin-10 gene knock-out mice: a model of chronic inflammation. Clin. Immunol. Immunopathol. 1995;76:S174-S178.

    Not in our library10.1016/s0090-1229(95)90144-2

  158. 158.

    Rhen T., Cidlowski J.A. Antiinflammatory action of glucocorticoids - new mechanisms for old drugs. N. Engl. J. Med. 2005;353:1711-1723.

    Not in our library10.1056/nejmra050541

  159. 159.

    Richards D.F., Fernandez M., Caulfield J., Hawrylowicz C.M. Glucocorticoids drive human CD8(+) T cell differentiation towards a phenotype with high IL-10 and reduced IL-4 IL-5 and IL-13 production. Eur. J. Immunol. 2000;30:2344-2354.

    Not in our library10.1002/1521-4141(2000)30:8<2344::aid-immu2344>3.0.co;2-7

  160. 160.

    Rogatsky I., Wang J.C., Derynck M.K., Nonaka D.F., Khodabakhsh D.B., Haqq C.M., Darimont B.D., Garabedian M.J., Yamamoto K.R. Target-specific utilization of transcriptional regulatory surfaces by the glucocorticoid receptor. Proc. Natl. Acad. Sci. U.S.A. 2003;100:13845-13850.

    Not in our library10.1073/pnas.2336092100

  161. 161.

    Rook G.A., Hernandez-Pando R., Lightman S.L. Hormones, peripherally activated prohormones and regulation of the Th1/Th2 balance. Immunol. Today. 1994;15:301-303.

    Not in our library10.1016/0167-5699(94)90075-2

  162. 162.

    Rosenstock J., Banarer S., Fonseca V., Inzucchi S., Holllis G., Flores R., Levy R., Williams B., Huber R. Efficacy and safety of the 11β-HSD1 inhibitor, INCB13739, added to metformin therapy in patients with type 2 diabetes. 2009.

    Not in our library

  163. 163.

    Ruffell D., Mourkioti F., Gambardella A., Kirstetter P., Lopez R.G., Rosenthal N., Nerlov C. A CREB-C/EBPβ cascade induces M2 macrophage-specific gene expression and promotes muscle injury repair. Proc. Natl. Acad. Sci. U.S.A. 2009;106:17475-17480.

    Not in our library10.1073/pnas.0908641106

  164. 164.

    Rutella S., Lemoli R.M. Regulatory T cells and tolerogenic dendritic cells: from basic biology to clinical applications. Immunol. Lett. 2004;94:11-26.

    Not in our library10.1016/j.imlet.2004.04.015

  165. 165.

    Sai S., Esteves C.L., Kelly V., Michailidou Z., Anderson K., Coll A.P., Nakagawa Y., Ohzeki T., Seckl J.R., Chapman K.E. Glucocorticoid regulation of the promoter of 11β-hydroxysteroid dehydrogenase type 1 is indirect and requires C/EBPβ. Mol. Endocrinol. 2008;22:2049-2060.

    Not in our library10.1210/me.2007-0489

  166. 166.

    Sai S., Nakagawa Y., Sakaguchi K., Okada S., Takahashi H., Hongo T., Seckl J.R., Chapman K.E., Ohzeki T. Differential regulation of 11β-hydroxysteroid dehydrogenase-1 by dexamethasone in glucocorticoid-sensitive and -resistant childhood lymphoblastic leukemia. Leuk. Res. 2009;33:1696-1698.

    Not in our library10.1016/j.leukres.2009.04.016

  167. 167.

    Salojin K.V., Owusu I.B., Millerchip K.A., Potter M., Platt K.A., Oravecz T. Essential role of MAPK phosphatase-1 in the negative control of innate immune responses. J. Immunol. 2006;176:1899-1907.

    Not in our library10.4049/jimmunol.176.3.1899

  168. 168.

    Savill J., Dransfield I., Gregory C., Haslett C. A blast from the past: clearance of apoptotic cells regulates immune responses. Nat. Rev. Immunol. 2002;2:965-975.

    Not in our library10.1038/nri957

  169. 169.

    Savoldi G., Fenaroli A., Ferrari F., Rigaud G., Albertini A., Di Lorenzo D. The glucocorticoid receptor regulates the binding of C/EBPβ on the α1-acid glycoprotein promoter in vivo. DNA Cell Biol. 1997;16:1467-1476.

    Not in our library10.1089/dna.1997.16.1467

  170. 170.

    Schacke H., Berger M., Rehwinkel H., Asadullah K. Selective glucocorticoid receptor agonists (SEGRAs): novel ligands with an improved therapeutic index. Mol. Cell. Endocrinol. 2007;275:109-117.

    Not in our library10.1016/j.mce.2007.05.014

  171. 171.

    Scheinman R.I., Cogswell P.C., Lofquist A.K., Baldwin A.S. Role of transcriptional activation of IκBα in mediation of immunosuppression by glucocorticoids. Science. 1995;270:283-286.

    Not in our library10.1126/science.270.5234.283

  172. 172.

    Schmidt M., Weidler C., Naumann H., Anders S., Scholmerich J., Straub R.H. Reduced capacity for the reactivation of glucocorticoids in rheumatoid arthritis synovial cells: Possible role of the sympathetic nervous system? Arthritis Rheum. 2005;52:1711-1720.

    Not in our library10.1002/art.21091

  173. 173.

    Schroeder-Gloeckler J.M., Rahman S.M., Janssen R.C., Qiao L., Shao J., Roper M., Fischer S.J., Lowe E., Orlicky D.J., McManaman J.L., Palmer C., Gitomer W.L., Huang W., O’Doherty R.M., Becker T.C., Klemm D.J., Jensen D.R., Pulawa L.K., Eckel R.H., Friedman J.E. CCAAT/enhancer-binding protein-β deletion reduces adiposity, hepatic steatosis, and diabetes in Lepr(db/db) mice. J. Biol. Chem. 2007;282:15717-15729.

    Not in our library10.1074/jbc.m701329200

  174. 174.

    Seckl J.R. 11β-hydroxysteroid dehydrogenases. Encyclopedia Stress. 2000;2:413-421.

    Not in our library

  175. 175.

    Seckl J.R., Morton N.M., Chapman K.E., Walker B.R. Glucocorticoids and 11β-hydroxysteroid dehydrogenase in adipose tissue. Recent Prog. Horm. Res. 2004;59:359-393.

    Not in our library10.1210/rp.59.1.359

  176. 176.

    Serhan C.N., Savill J. Resolution of inflammation: the beginning programs the end. Nat. Immunol. 2005;6:1191-1197.

    Not in our library10.1038/ni1276

  177. 177.

    Shanks N., Windle R.J., Perks P.A., Harbuz M.S., Jessop D.S., Ingram C.D., Lightman S.L. Early-life exposure to endotoxin alters hypothalamic-pituitary-adrenal function and predisposition to inflammation. Proc. Natl. Acad. Sci. U.S.A. 2000;97:5645-5650.

    Not in our library10.1073/pnas.090571897

  178. 178.

    Sica A., Bronte V. Altered macrophage differentiation and immune dysfunction in tumor development. J. Clin. Invest. 2007;117:1155-1166.

    Not in our library10.1172/jci31422

  179. 179.

    Simons S.S. What goes on behind closed doors: physiological versus pharmacological steroid hormone actions. Bioessays. 2008;30:744-756.

    Not in our library10.1002/bies.20792

  180. 180.

    Smoak K.A., Cidlowski J.A. Mechanisms of glucocorticoid receptor signaling during inflammation. Mech. Ageing Dev. 2004;125:697-706.

    Not in our library10.1016/j.mad.2004.06.010

  181. 181.
    Determinants of Cell- and Gene-Specific Transcriptional Regulation by the Glucocorticoid Receptor · 2007
    No notice
  182. 182.

    So A.Y., Cooper S.B., Feldman B.J., Manuchehri M., Yamamoto K.R. Conservation analysis predicts in vivo occupancy of glucocorticoid receptor-binding sequences at glucocorticoid-induced genes. Proc. Natl. Acad. Sci. U.S.A. 2008;105:5745-5749.

    Not in our library10.1073/pnas.0801551105

  183. 183.

    Solito E., Mulla A., Morris J.F., Christian H.C., Flower R.J., Buckingham J.C. Dexamethasone induces rapid serine-phosphorylation and membrane translocation of annexin 1 in a human folliculostellate cell line via a novel nongenomic mechanism involving the glucocorticoid receptor, protein kinase C, phosphatidylinositol 3-kinase, and mitogen-activated protein kinase. Endocrinology. 2003;144:1164-1174.

    Not in our library10.1210/en.2002-220592

  184. 184.

    Sorrells S.F., Caso J.R., Munhoz C.D., Sapolsky R.M. The stressed CNS: when glucocorticoids aggravate inflammation. Neuron. 2009;64:33-39.

    Not in our library10.1016/j.neuron.2009.09.032

  185. 185.

    Souverein P.C., Berard A., Van Staa T.P., Cooper C., Egberts A.C.G., Leufkens H.G.M., Walker B.R. Use of oral glucocorticoids and risk of cardiovascular and cerebrovascular disease in a population based case-control study. Heart. 2004;90:859-865.

    Not in our library10.1136/hrt.2003.020180

  186. 186.

    Staiger J., Lueben M.J., Berrigan D., Malik R., Perkins S.N., Hursting S.D., Johnson P.F. C/EBPβ regulates body composition, energy balance-related hormones, and tumor growth. Carcinogenesis. 2008;30:832-840.

    Not in our library10.1093/carcin/bgn273

  187. 187.

    Stavreva D.A., Wiench M., John S., Conway-Campbell B.L., McKenna M.A., Pooley J.R., Johnson T.A., Voss T.C., Lightman S.L., Hager G.L. Ultradian hormone stimulation induces glucocorticoid receptor-mediated pulses of gene transcription. Nat. Cell Biol. 2009;11:1093-1102.

    Not in our library10.1038/ncb1922

  188. 188.

    Stellato C. Post-transcriptional and nongenomic effects of glucocorticoids. Proc. Am. Thorac. Soc. 2004;1:255-263.

    Not in our library10.1513/pats.200402-015ms

  189. 189.

    Sternberg E.M. Neural regulation of innate immunity: a coordinated nonspecific host response to pathogens. Nat. Rev. Immunol. 2006;6:318-328.

    Not in our library10.1038/nri1810

  190. 190.

    Tchen C.R., Martins J.R., Paktiawal N., Perelli R., Saklatvala J., Clark A.R. Glucocorticoid regulation of mouse and human dual specificity phosphatase 1 (DUSP1) genes: unusual cis-acting elements and unexpected evolutionary divergence. J. Biol. Chem. 2009;(November (23)).

    Not in our library10.1074/jbc.m109.037309

  191. 191.

    Thieringer R., Le Grand C.B., Carbin L., Cai T.Q., Wong B., Wright S.D., Hermanowski-Vosatka A. 11β-Hydroxysteroid dehydrogenase type 1 is induced in human monocytes upon differentiation to macrophages. J. Immunol. 2001;167:30-35.

    Not in our library10.4049/jimmunol.167.1.30

  192. 192.

    Tuckermann J.P., Kleiman A., McPherson K.G., Reichardt H.M. Molecular mechanisms of glucocorticoids in the control of inflammation and lymphocyte apoptosis. Crit. Rev. Clin. Lab Sci. 2005;42:71-104.

    Not in our library10.1080/10408360590888983

  193. 193.

    Tuckermann J.P., Kleiman A., Moriggl R., Spanbroek R., Neumann A., Illing A., Clausen B.E., Stride B., Forster I., Habenicht A.J., Reichardt H.M., Tronche F., Schmid W., Schutz G. Macrophages and neutrophils are the targets for immune suppression by glucocorticoids in contact allergy. J. Clin. Invest. 2007;117:1381-1390.

    Not in our library10.1172/jci28034

  194. 194.

    Umesono K., Evans R.M. Determinants of target gene specificity for steroid/thyroid hormone receptors. Cell. 1989;57:1139-1146.

    Not in our library10.1016/0092-8674(89)90051-2

  195. 195.

    van der Laan S., Sarabdjitsingh R.A., Van Batenburg M.F., Lachize S.B., Li H., Dijkmans T.F., Vreugdenhil E., de Kloet E.R., Meijer O.C. Chromatin immunoprecipitation scanning identifies glucocorticoid receptor binding regions in the proximal promoter of a ubiquitously expressed glucocorticoid target gene in brain. J. Neurochem. 2008;106:2515-2523.

    Not in our library10.1111/j.1471-4159.2008.05575.x

  196. 196.

    van Staa T.P., Leufkens H.G.M., Abenhaim L., Begaud B., Zhang B., Cooper C. Use of oral corticosteroids in the United Kingdom. QJM. 2000;93:105-111.

    Not in our library10.1093/qjmed/93.2.105

  197. 197.

    van Tilborg M.A., Lefstin J.A., Kruiskamp M., Teuben J., Boelens R., Yamamoto K.R., Kaptein R. Mutations in the glucocorticoid receptor DNA-binding domain mimic an allosteric effect of DNA. J. Mol. Biol. 2000;301:947-958.

    Not in our library10.1006/jmbi.2000.4001

  198. 198.

    Varga G., Ehrchen J., Tsianakas A., Tenbrock K., Rattenholl A., Seeliger S., Mack M., Roth J., Sunderkoetter C. Glucocorticoids induce an activated, anti-inflammatory monocyte subset in mice that resembles myeloid-derived suppressor cells. J. Leukoc. Biol. 2008;84:644-650.

    Not in our library10.1189/jlb.1107768

  199. 199.

    Vegiopoulos A., Herzig S. Glucocorticoids, metabolism and metabolic diseases. Mol. Cell Endocrinol. 2007;275:43-61.

    Not in our library10.1016/j.mce.2007.05.015

  200. 200.

    Wang D., Muller N., McPherson K.G., Reichardt H.M. Glucocorticoids engage different signal transduction pathways to induce apoptosis in thymocytes and mature T cells. J. Immunol. 2006;176:1695-1702.

    Not in our library10.4049/jimmunol.176.3.1695

  201. 201.

    Wang J.C., Derynck M.K., Nonaka D.F., Khodabakhsh D.B., Haqq C., Yamamoto K.R. Chromatin immunoprecipitation (ChIP) scanning identifies primary glucocorticoid receptor target genes. Proc. Natl. Acad. Sci. U.S.A. 2004;101:15603-15608.

    Not in our library10.1073/pnas.0407008101

  202. 202.

    Webster J.I., Tonelli L., Sternberg E.M. Neuroendocrine regulation of immunity. Annu. Rev. Immunol. 2002;20:125-163.

    Not in our library10.1146/annurev.immunol.20.082401.104914

  203. 203.

    Wei L., MacDonald T.M., Walker B.R. Taking glucocorticoids by prescription is associated with subsequent cardiovascular disease. Ann. Intern. Med. 2004;141:764-770.

    Not in our library10.7326/0003-4819-141-10-200411160-00007

  204. 204.

    White P.C., Rogoff D., McMillan D.R., Lavery G.G. Hexose 6-phosphate dehydrogenase (H6PD) and corticosteroid metabolism. Mol. Cell. Endocrinol. 2007;265-266:89-92.

    Not in our library10.1016/j.mce.2006.12.022

  205. 205.

    Whorwood C.B., Franklyn J.A., Sheppard M.C., Stewart P.M. Tissue localisation of 11β-hydroxysteroid dehydrogenase and its relationship to the glucocorticoid receptor. J. Steroid Biochem. Mol. Biol. 1992;41:21-28.

    Not in our library10.1016/0960-0760(92)90220-d

  206. 206.

    Whyte M.K., Meagher L.C., MacDermot J., Haslett C. Impairment of function in aging neutrophils is associated with apoptosis. J. Immunol. 1993;150:5124-5134.

    Not in our library

  207. 207.

    Wilckens T. Glucocorticoids and immune function: physiological relevance and pathogenic potential of hormonal dysfunction. Trends Pharmacol. Sci. 1995;16:193-197.

    Not in our library10.1016/s0165-6147(00)89021-5

  208. 208.

    Wilckens T., De Rijk R. Glucocorticoids and immune function: unknown dimensions and new frontiers. Immunol. Today. 1997;18:418-424.

    Not in our library10.1016/s0167-5699(97)01111-0

  209. 209.

    Williams L.J.S., Lyons V., MacLeod I., Rajan V., Darlington G.J., Poli V., Seckl J.R., Chapman K.E. C/EBP regulates hepatic transcription of 11β-hydroxysteroid dehydrogenase type 1; a novel mechanism for cross talk between the C/EBP and glucocorticoid signalling pathways. J. Biol. Chem. 2000;275:30232-30239.

    Not in our library10.1074/jbc.m001286200

  210. 210.

    Wissink S., van Heerde E.C., vand der Burg B., van der Saag P.T. A dual mechanism mediates repression of NF-κB activity by glucocorticoids. Mol. Endocrinol. 1998;12:355-363.

    Not in our library10.1210/mend.12.3.0081

  211. 211.

    Wu J.J., Roth R.J., Anderson E.J., Hong E.-G., Lee M.-K., Choi C.S., Neufer P.D., Shulman G.I., Kim J.K., Bennett A.M. Mice lacking MAP kinase phosphatase-1 have enhanced MAP kinase activity and resistance to diet-induced obesity. Cell Metab. 2006;4:61-73.

    Not in our library10.1016/j.cmet.2006.05.010

  212. 212.

    Wust S., van den Brandt J., Tischner D., Kleiman A., Tuckermann J.P., Gold R., Luhder F., Reichardt H.M. Peripheral T cells are the therapeutic targets of glucocorticoids in experimental autoimmune encephalomyelitis. J. Immunol. 2008;180:8434-8443.

    Not in our library10.4049/jimmunol.180.12.8434

  213. 213.

    Yamada K., Duong D.T., Scott D.K., Wang J.-C., Granner D.K. CCAAT/enhancer-binding protein β is an accessory factor for the glucocorticoid response from the cAMP response element in the rat phosphoenolpyruvate carboxykinase gene promoter. J. Biol. Chem. 1999;274:5880-5887.

    Not in our library10.1074/jbc.274.9.5880

  214. 214.

    Yamamoto K.R. Steroid receptor regulated transcription of specific genes and gene networks. Ann. Rev. Genet. 1985;19:209-252.

    Not in our library10.1146/annurev.ge.19.120185.001233

  215. 215.

    Yang H., Mammen J., Wei W., Menconi M., Evenson A., Fareed M., Petkova V., Hasselgren P.O. Expression and activity of C/EBPβ and δ are upregulated by dexamethasone in skeletal muscle. J. Cell. Physiol. 2005;204:219-226.

    Not in our library10.1002/jcp.20278

  216. 216.

    Yang H., Menconi M.J., Wei W., Petkova V., Hasselgren P.O. Dexamethasone upregulates the expression of the nuclear cofactor p300 and its interaction with C/EBPβ in cultured myotubes. J. Cell. Biochem. 2005;94:1058-1067.

    Not in our library10.1002/jcb.20371

  217. 217.

    Yang Y.H., Aeberli D., Dacumos A., Xue J.R., Morand E.F. Annexin-1 regulates macrophage IL-6 and TNF via glucocorticoid-induced leucine zipper. J. Immunol. 2009;183:1435-1445.

    Not in our library10.4049/jimmunol.0804000

  218. 218.

    Yang Y.H., Morand E.F., Getting S.J., Paul-Clark M., Liu D.L., Yona S., Hannon R., Buckingham J.C., Perretti M., Flower R.J. Modulation of inflammation and response to dexamethasone by Annexin 1 in antigen-induced arthritis. Arthritis Rheum. 2004;50:976-984.

    Not in our library10.1002/art.20201

  219. 219.

    Yang Z., Guo C., Zhu P., Li W., Myatt L., Sun K. Role of glucocorticoid receptor and CCAAT/enhancer-binding protein-α in the feed-forward induction of 11β-hydroxysteroid dehydrogenase type 1 expression by cortisol in human amnion fibroblasts. J. Endocrinol. 2007;195:241-253.

    Not in our library10.1677/joe-07-0303

  220. 220.

    Yang Z., Zhu X., Guo C., Sun K. Stimulation of 11β-HSD1 expression by IL-1β via a C/EBP binding site in human fetal lung fibroblasts. Endocrine. 2009;36:404-411.

    Not in our library10.1007/s12020-009-9245-4

  221. 221.

    Yangyen H.F., Chambard J.C., Sun Y.L., Smeal T., Schmidt T.J., Drouin J., Karin M. Transcriptional interference between c-Jun and the glucocorticoid receptor: mutual inhibition of DNA binding due to direct protein-protein interaction. Cell. 1990;62:1205-1215.

    Not in our library10.1016/0092-8674(90)90396-v

  222. 222.

    Yeager M.P., Guyre P.M., Munck A.U. Glucocorticoid regulation of the inflammatory response to injury. Acta Anaesthesiol. Scand. 2004;48:799-813.

    Not in our library10.1111/j.1399-6576.2004.00434.x

  223. 223.

    Yona S., Buckingham J.C., Perretti M., Flower R.J. Stimulus-specific defect in the phagocytic pathways of annexin 1 null macrophages. Br. J. Pharmacol. 2004;142:890-898.

    Not in our library10.1038/sj.bjp.0705858

  224. 224.

    Yoshinaga S.K., Yamamoto K.R. Signaling and regulation by a mammalian glucocorticoid receptor in Drosophila cells. Mol. Endocrinol. 1991;5:844-853.

    Not in our library10.1210/mend-5-6-844

  225. 225.

    Zbankova S., Bryndova J., Leden P., Kment M., Svec A., Pacha J. 11β-hydroxysteroid dehydrogenase 1 and 2 expression in colon from patients with ulcerative colitis. J. Gastroenterol. Hepatol. 2007;22:1019-1023.

    Not in our library10.1111/j.1440-1746.2006.04529.x

  226. 226.

    Zhang J., Ge R., Matte-Martone C., Goodwin J., Shlomchik W.D., Mamula M.J., Kooshkabadi A., Hardy M.P., Geller D. Characterization of a novel gain of function glucocorticoid receptor knock-in mouse. J. Biol. Chem. 2009;284:6249-6259.

    Not in our library10.1074/jbc.m807997200

  227. 227.

    Zhang T.Y., Daynes R.A. Macrophages from 11β-hydroxysteroid dehydrogenase type 1-deficient mice exhibit an increased sensitivity to lipopolysaccharide stimulation due to TGF-β-mediated up-regulation of SHIP1 expression. J. Immunol. 2007;179:6325-6335.

    Not in our library10.4049/jimmunol.179.9.6325

  228. 228.

    Zhang T.Y., Ding X., Daynes R.A. The expression of 11β-hydroxysteroid dehydrogenase type I by lymphocytes provides a novel means for intracrine regulation of glucocorticoid activities. J. Immunol. 2005;174:879-889.

    Not in our library10.4049/jimmunol.174.2.879

  229. 229.

    Zhao Q., Wang X., Nelin L.D., Yao Y., Matta R., Manson M.E., Baliga R.S., Meng X., Smith C.V., Bauer J.A., Chang C.H., Liu Y. MAP kinase phosphatase 1 controls innate immune responses and suppresses endotoxic shock. J. Exp. Med. 2006;203:131-140.

    Not in our library10.1084/jem.20051794

Cited by papers we hold 18

Reads

Read by people on this page

None yet.

Checked or read by AI through naulon

None yet.

A person counts once a day per paper. We keep no cookie and no address: a reader is a hash that changes every day. Any month under five reads shows no number.

Are you an author?

Is this your paper?

Claim it to add your note and be paid when agents cite it. Free.